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A. Project Overview 
 Activated transcription is a complex process that is governed by the interactions 
of several different proteins.  One essential protein-protein interaction that governs 
transcription is that of a DNA bound transcriptional activator with co-activator proteins.  
Two co-activators, CBP and p300, are highly homologous proteins that play key roles in 
several cellular processes including cell growth, differentiation, cell-cycle regulation and 
apoptosis.  As these proteins are involved in so many processes, considerable interest has 
been devoted to identifying small molecules that can modulate the function of these 
proteins in defined ways.  These small molecules can act as probes for dissecting the 
roles of CBP and p300 in various cellular processes. 
 My thesis work has focused in part on the design, synthesis and application of 
small molecules that can be used to modulate the functions of CBP and p300.  This work 
has taken on several forms.  First, I will discuss a novel methodology for the synthesis of 
a class of building block substrates that can be used in the synthesis of a wide variety of 
highly functionalized heterocycles which can be assayed for their ability to modulate 
transcription.  Second, I will discuss the use of small molecule modulators of 
transcription in altering the phenotype of a specific set of cancer cells.  Finally, I will
 2 
 discuss the design and synthesis of a focused library of small molecules that were 
designed to modulate the activity of a specific domain of CBP/p300. 
 
B. Introduction to Transcription 
 
 Transcription is the process by which DNA is converted to messenger RNA 
(mRNA) which leads to the synthesis of proteins that are regulated by a specific gene.
1
  
In order for activated transcription to proceed, transcription factors must bind to a 
specific site on DNA.  Once these transcription factors are in place, they recruit the 
proteins necessary to modify chromatin structure and initiate mRNA synthesis.
1,2
  One of 
the proteins recruited during this event is RNA polymerase II (RNA Pol II),  the enzyme 
directly responsible for the formation of mRNA.
2
   
 One type of transcription, activated transcription, relies on a modular protein 
termed an activator protein that must be present to activate transcription.  Activator 
proteins consist minimally of a transcription activation domain (TAD) which is 
responsible for binding members of the transcriptional machinery and a DNA binding 
domain (DBD) which binds to specific sites on DNA.  The DBDs bind to sites on the 
DNA known as enhancers which are located upstream of the promoter region.
2,3,4
 The 
TADs can then activate transcription by binding with co-factors which aid in the 
assembly of the pre-initiation complex (PIC) at the promoter of the gene to be transcribed.  
There are a wide variety of proteins involved in activated mammalian transcription 
including: bridging co-factors such as the Creb Binding Protein (CBP) and its paralog 
p300, complexes that modulate histone acetylation such as CBP/p300 (histone 
 3 
acetyltransferases) and Swi/Snf, SAGA (histone deacetylases) the mediator complex,  
and members of the general transcription machinery such as general transcription factors 
(GTFs), the TATA binding protein (TBP),  TBP associated factors (TAFs) and RNA Pol 
II.
2,4 
Activated transcription begins in response to intra-or extra-cellular stimuli.  These 
stimuli can trigger several changes within the cell that allow transcription to occur.  One 
common initial response to these stimuli involves bringing the activator protein into a 
state where it can effectively interact with both DNA and its relevant co-factors in the 






. Schematic of activated transcription.  Activator proteins are responsible for 
initiating activated transcription.  The activators consist minimally of two domains. The 
transcriptional activation domain (TAD) (here a red square) is responsible for contacting 
members of the transcriptional machinery.  The DNA binding domain (DBD) (here a blue 
oval) is responsible for contacting specific sites on DNA   These domains work together 
to promote binding of cofactors and other members of the transcriptional machinery to 
specific sites on DNA.  When active transcription is not necessary, activator proteins are 
rendered inoperable by the cell via a variety of mechanisms including: interactions with 
masking proteins (mps), aggregation, and proteolytic degradation. 
  
 
 Upon binding to DNA, the transcriptional activator then recruits co-factors via 
direct binding interactions.
6,7  
Co-factors (or co-activators) are proteins or protein 
 4 
complexes that do not bind directly to DNA but serve as a bridge between DNA-bound 
activators and members of the general transcriptional machinery.
1,2
  There are a large 
number of co-factors which serve diverse functions including histone modification and 
bridging the transcriptional activator and RNA Pol II holoenzyme.
2,3
  The bridging co-
factors serve a key role in transcription as it has been shown in a reconstituted yeast 
system that when activators are in the presence of RNA Pol II and GTFs but in the 
absence of other co-factors, transcription does not occur.  Upon the introduction of the 
co-factor Mediator, transcription function is restored.
1,2,3, 8  
 Additional co-factors such as the Swi/Snf complex and the SAGA complex have 
been shown to modify the nucleosomes in both yeast and mammalian cells.
1,2,9,10
  
Chromatin modification is necessary for transcription as interactions between DNA and 
the nucleosomes may inhibit transcription by blocking sites on DNA necessary for 
binding by activators and other members of the transcriptional machinery.
 9,10
 Other 
important co-factors in mammalian cells are the Creb binding protein (CBP) and its 
paralog p300.  These co-factors have no known homologs in yeast, but have been 
implicated in the transcription of many mammalian genes.  They have been shown in 




 While it is generally accepted that recruitment of co-activators via activator 
proteins is an essential step in activated transcription, the exact timing and nature of these 
interactions is poorly understood.
 
   
C. Activator Proteins 
 5 
 
 As the name suggests, activated transcription is largely governed by a class of 
proteins known as transcriptional activators.  These proteins are modular in nature and 
are minimally composed of a transcriptional activation domain (TAD) and a DNA 
binding domain (DBD).  This modularity has interesting implications for activator 
construction as it has been shown that functional activators can be synthesized by 




One piece of evidence for the role of activators in recruiting the transcriptional 
machinery to DNA comes from activator bypass experiments. In these experiments, 
portions of the RNA Pol II holoenzyme (the term given to the mega-complex formed 
between RNA Pol II and the transcription co-factors) are directly fused to a protein 
capable of binding the DNA without the incorporation of an activating region.
1,2, 11
  It has 
been shown in several different studies that the level of activation achieved by these 
fusion proteins equals that achieved by endogenous activators, thus suggesting the role of 
the transcriptional activator protein as a link between the DNA and the transcriptional 
machinery.
2,3,4,5,6,7 
The binding of activators to their co-factors have been linked to the maintenance 
of disease states.  One example is the hypoxia inducible factor-1α (HIF-1α).  This 
transcription factor is necessary for the expression of genes involved in maintaining 
homeostasis under hypoxic conditions, such as those found in solid tumors.
12
  The TAD 
of HIF-1α has been shown by a variety of methods to interact with the CH1 domain of 
the co-factor p300.
13,14  
Livingston and co-workers have shown that by disruption of the 
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interaction of HIF-1α with p300 is sufficient to cause a decrease in cellular survival under 
hypoxic conditions.
13
  Additionally, disruption of this interaction suppresses tumor 









The DNA binding domain is responsible for binding to DNA in a gene-specific 
manner.
1,2
  In general, the DBD acts by interacting with either the major or minor groove 
of B-form DNA.
15
  While there is no exact “code” for DNA recognition, several general 
features that contribute to binding specificity and stability have been identified.  The 
DBD presents a complementary face to its target DNA strand and imparts specificity 
through van der Waals forces, water-mediated hydrogen bonds, amino acid·base pair 
hydrogen bonding and favorable electrostatic interactions.  Additional stability is 
imparted by interactions with the negatively charged phosphate backbone, specifically 




Nuclear magnetic resonance (NMR) and x-ray crystallographic studies of DBDs 
reveal that they are globular proteins that can fold into a wide array of different structural 
motifs that are responsible for providing the specificity and stability of protein/DNA 
interactions (see Figure I-2 for examples).  The most commonly used secondary structure 
is the α-helix.  This structure is employed in a variety of motifs including the 
homeodomain motif and the basic region leucine zipper (bZIP). 
2,15  
Additionally, several 
types of DBD motifs (including the zinc-finger motifs and the zinc-cluster motifs) 
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coordinate to one or more zinc molecules.
15
  Because of this wealth of structural 
information, the formation of artificial DBDs has proven to be a tractable target for 
exogenous regulation of transcription. 
 
Figure I-2. DBD·DNA interactions. a) Ribbon diagram of the crystal structure of the 
Gal4-DNA binding domain bound to DNA as a dimer.  The Gal4-DNA binding domain 
utilizes a zinc cluster binding motif (PDB ID: 1D66). b) Ribbon diagram of the crystal 
structure of GCN4-DBD bound to DNA using a basic leucine zipper (bZIP) motif (PDB 
ID: 1YSA).  
 
 
C. 2. Transcriptional Activation Domains (TADs) 
 
In contrast to DBDs, which are characterized by their structural motifs, 
transcriptional activation domains are characterized by their amino acid sequences.
1,2 
 
The most abundant class of activators is the amphipathic class (sometimes referred to as 
the acidic class) which consists of an interspersion of hydrophobic and polar residues; 
however, glutamine and proline rich activators have also been identified.
1,2,17
 
Amphipathic transcription activators are intrinsically unstructured in solution.
2,18 
 
NMR structures of several amphipathic activators including ESX, VP16, c-Myb, CREB, 
MLL, p53, and HIF-1α, have shown that these activators adopt a helical structure upon 
binding their endogenous co-factors (Figure I-3).
2,14,19,20,21




are displayed along one face of the helix.  It is this hydrophobic face that is generally 




Figure I-3. TAD-target interactions. a) Ribbon diagram of the NMR structure of the 
minimal activation domain of the HIF-1α TAD (blue) bound to the CH1 domain of CBP 
(yellow) (PDB ID: 1L8C). b) Stereoview of the ribbon diagram of the NMR structure of 
the MLL TAD (cyan) and the Myb TAD (magenta) co-bound to the KIX domain of CBP 
(yellow) (PDB ID: 2AGH). 
 
The TAD is responsible for contacting members of the transcriptional machinery 
to localize them to DNA.  Using a potent amphipathic activator derived from the herpes 
simplex virus (VP16) as a model of amphipathic activators, several groups have 
demonstrated the ability of these activators to bind to the GTF TFIIB and to TBP.
24,25
  It 
is postulated that the binding of amphipathic activators to TFIIB is critical for the stable 
formation of the PIC.
25  




with other members of the transcriptional machinery including CBP/p300, other GTFs 
and RNA Pol II.
2
  Indeed, amphipathic transcriptional activators are known to exhibit a 
multi-partner binding profile with many of these interactions being transient and of 
medium affinity.  This makes it difficult to identify and characterize all of the relevant 
binding partners of a given activator.
1,2 
 
C.3. Mis-regulation of Transcription in Diseases 
 
The mis-regulation of transcription has been implicated in many disease states 
including several types of cancers, schizophrenia, diabetes and sickle cell 
anemia.
26,27,28,29,30 
   In order for effective therapeutics to be developed, the interactions 
between transcriptional activators implicated in diseases and the co-factors that bind them 
must be better understood.
26 
 Two co-factors that have been shown to bind several 
transcription factors implicated in disease states are the Creb Binding Protein (CBP) and 
its paralog p300.
 31,32
  Studies have shown that disrupting the binding between CBP/p300 
and HIF-1α (a transcription factors involved several types of solid-tumor cancers) has 
induced a decrease in tumor-size in a mouse model.
13
 The study of the interactions 
between CBP/p300 and TADs could provide essential information for the formation of 
effective therapeutics. 
 
D. Roles of CBP/p300 in Regulating Transcription 
 
 10 
 The mammalian co-activators CBP and p300 are large, multi-domain proteins that 
play key roles in several cellular processes including cell growth, differentiation, cell-
cycle regulation and apoptosis.
31,32,33,34,35
  The importance of CBP is underscored by its 









 genotypes impart embryonic lethality.
36
  
Haploinsufficiency for CBP in humans is the cause of Rubinstein-Taybi syndrome (a 
genetic disorder characterized by mental retardation, skeletal abnormalities and neoplasia) 
and sequestering of CBP has been linked with poly glutamine disorders such as 
Huntington’s Disease.
31,37
  Additionally, while p300 and CBP are highly homologous 
proteins (and are often referred to interchangeably) with certain overlapping functions, 
they also have distinct cellular roles.  For example in both embryonal carcinoma (EC) 
cells and in hematopoietic stem cells (HSCs), CBP has been implicated in self renewal 
whereas p300 has been shown to play a key role in differentiation.
33,38
  
 CBP and p300 share several functional domains that are responsible for 
interacting with a large number of transcriptional activators.  These domains include an 
N-terminal receptor interacting domain (RID), three cysteine-histidine rich domains 
(CH1-3), a KIX domain, a bromo-domain (BD), a steroid receptor coactivator-1 
interacting domain (SID) and a Glutamine rich domain (QP)
31,32
 (Figure I-4).  The region 
of CBP/p300 encompassing the BD and CH2 domains also acts as a histone 
acetyltransferase (HAT).  These domains have been shown to bind a number of different 







Figure I-4. Schematic of CBP/p300.  These proteins each contain a number of highly 
conserved domains.  These domains have been shown to bind to a myriad of different 
proteins.  The region responsible for acetyltransferase activity is indicated.   
  
 As CBP and p300 have the ability to bind to many different transcription 
activators, one of their main roles in regulating transcription is to serve as a bridge 
between DNA-bound activators and the basal transcriptional machinery.
39
  Several 
transcription factors that are linked with disease states such as the hypoxia inducible 
factor 1 (HIF-1α), the tumor suppressor protein p53, and the viral proteins Tat, Tax and 
E1A have been shown to bind to CBP/p300.
31,32,34,35,39
  Additionally, it has been shown 
that both CBP and p300 interact with TFIIB (a GTF) and TBP, thus providing a link 
between activators and the transcriptional machinery.
40
  
 In addition to this bridging functionality, CBP and p300 have acetyl transferase 
activity.
33  
Studies in the Roeder laboratories utilizing chromatin imunnoperciptiation 
(ChIP) have shown that following or concomitant with activator binding, CBP/p300 
specifically acetylates histones proximal the promoters at which they are bound.
41
  It was 
also found that this acetylation was necessary for transcription to occur as ablation of 
HAT activity (either by addition of a small molecule HAT inhibitor or removal of the co-




CBP/p300 play another role in regulating transcription via their ability to 
acetylate other proteins, including certain transcription factors.
32
  One example of this 
function is in regulating the expression of the interferon-β (IFNβ) gene.  This gene is 
regulated by the assembly of several distinct proteins, including the high mobility group 
protein (HMG1) which acts as a scaffold for the binding of the other proteins.  CBP has 
been shown to acetylate HMG1 at a key lysine residue, causing HMG1 to de-associate 
from DNA, resulting in down regulation of the IFNβ gene expression.
42
  
Most of what is known about the roles of CBP/p300 comes from studies 
performed in differentiated adult cells.  Evidence is emerging, however, that CBP/p300 
may play an important role in regulating the transcription of undifferentiated cells such as 
embryonic stem cells, hematopoietic stem cells, and cancer imitating cells.  
 
D.1. CBP/p300 in Cancer Initiating Cells (CICs) 
 
Cancer initiating (CI) cells (also referred to as cancer stem cells (CSCs)) are a 
sub-population of cancer cells that exhibit stem cell-like qualities such as pluripotency 
and self-renewal and are postulated to be largely responsible for tumor growth.
43
   These 
CI cells are biochemically distinct from differentiated adult cells; however, they display a 
gene expression signature similar to embryonic stem cells (ESCs) including reliance on 
distinct regulatory networks and transcription factors.
44,45,46
  Cancers that exhibit a greater 
degree of ESC-like gene set enrichment are generally more poorly differentiated and are 




Three key transcription factors, Oct4, Nanog, and Sox2, are central in governing 
the expression of genes that promote pluripotency and self renewal in ESCs.
47
  These 
activators also tend to be over-expressed in several types of cancers.
44
  To date, very little 
is known about the mechanisms by which these three transcription factors regulate 
pluripotency and self renewal.  Emerging evidence suggests, however, that CBP and/or 
p300 may play a role in regulating these factors.  The discussion in Chapter 3 will further 
address the roles of these co-factors in regulating cancer initiating cells. 
Chen and co-workers used chromatin immunopercipitation coupled with ulta-
high-throughput DNA sequencing (ChIP-seq) in ESCs to map the locations of stem cell 
activators including Oct4, Nanog and Sox2, as well as the location of p300.  They found 
that p300 co-occurred with Oct4-Nanog-Sox2 binding sites, suggesting that one or more 
of these factors may be capable of recruiting p300.  Accordingly, they found that when 
RNA interference (RNAi) targeted against any of these three factors was introduced to 
the cell, there was a reduction in p300 binding at these sites.
48
  Additionally, work carried 
out in mouse ESCs suggests that p300 aids in Nanog-driven gene expression by 
acetylating a distal regulatory region of the Nanog promoter.
49
  
In cellulo studies indicate a role of p300 in Sox2 mediated transcription.  Using 
chimeric fusion proteins comprised of the Gal4 DBD and the Sox2 TAD, Knowlings and 
co-workers examined the effects of p300 on a Sox2-driven reporter system.  They found 
an increased level of transcription when p300 was introduced into the cell.  Conversely, 
they found that when a protein capable of sequestering endogenous p300 (E1A) was 
introduced, transcription levels decreased in a dose dependant manner.
50
  Activator by-
pass experiments performed in a follow up study in which p300 was fused directly to the 
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Gal4 DBD resulted in increased levels of transcription in a similar reporter system.
51
  
These experiments indicate that p300 plays a role in Sox2-mediated transcription. 
 
E. Small Molecules as Tools for Probing Transcription  
 
Mis-regulation of transcription has been implicated in several disease states 
including cancer, diabetes and schizophrenia.
27,29,30  
As such, there has been much effort 
focused on finding exogenous modulators of transcription.
 52,53,54
  In this section, the 
design of artificial probes for studying TAD·co-activator interactions will be discussed 
(Figure I-5).  
 
Figure I-5. Schematic of inhibition of a TAD·co-activator interaction.  Left: Under 
endogenous conditions, the TAD of the DNA bound activator is able to interact with its 
relevant co-factor and transcription of the gene proceeds.  Right: When a small molecule 
ligand of the co-factor (here a purple wedge) is introduced, it binds to the co-factor thus 
preventing the co-factor from interacting with the TAD.  Small molecules that can 
perturb the functionality of specific co-factors can be used to study the role(s) of these 
co-factors in specific transcriptional processes and help to determine the role(s) they play 
in maintaining certain cellular phenotypes. 
 
 




One of the complicating factors in designing small molecules that can perturb 
activator·co-activator interactions is the ability of endogenous TADs to interact with 
several different proteins, or several different regions of the same protein.
2 
  For example, 
the TAD of the tumor suppressor protein, p53, has been shown to bind CBP/p300 at four 
distinct sites (the CH1, CH3, KIX, and SID domains).  p53 has also been observed to 
bind several members of the basal transcriptional machinery as well as its suppressor 
protein, MDM2 (Figure I-6).
55
  This promiscuity is owed in large part to the intrinsically 
unstructured TADs’ ability to bind to several different targets and may help provide a 
mechanism for regulating transcription.
56
    
 
Figure I-6. p53 binding with two distinct proteins. a) Ribbon diagram of the NMR 
structure of the p53 TAD (red) bound as an α-helix to the CH3 domain of p300 (yellow) 
(PDB ID: 2K8F). b) Ribbon diagram of the crystal structure of the p53 TAD (red) bound 
as an α-helix to its suppressor protein MDM2 (silver) (PDB ID: 1YCR). 
 
Another factor that complicates the development of small molecule modulators of 
transcription is that several co-factors are able to interact with multiple different TADs.  
The KIX domain of CBP, for example, has been shown to interact with over 12 different 
amphipathic TADs.
52
  To further complicate matters, it has been shown that many of 





of the interacting proteins are poorly defined.
53
 These types of transient, low affinity 
interactions make the design of artificial modulators of transcription exceedingly 
challenging.  In order to meet these this challenge, a broad approach to small molecule 
design must be taken as it seems unlikely that a single class or type of scaffold will be 
able to selectively modulate all of these disparate transcription events.  One way to 
efficiently synthesize a diverse library of structures is to utilize a common building block 
molecule that can be further transformed to a wide variety of structures.  
 
E.1.A. Novel Methodology for the Synthesis of Allenamides as a 
Building Block Scaffold  
 
 
 Allenamides are an especially promising building block substrate as they 












 (Figure I-7).  
Thus, significant efforts have been devoted towards general methodologies to access 
allenamides; however, these methodologies are often lengthy or require complex 
precursor syntheses.
64
 One intriguing route for the formation of allenamides involves the 
[3,3]-rearrangement of propargylic tricholoroacetimidates.
65,66
  While this reaction 
proceeded in poor yields (10-20%) it showed that a [3,3]-rearrangement could be used in 
the formation of allenamides.
65,66
  Previous work carried out in the Mapp laboratories 
focused on a novel [3,3]-rearrangement of a phosphorimidate to a phosphoramidate for 
the synthesis of allylic amides.
67,68
  Work discussed in Chapter 2 will demonstrate that 
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this strategy can be applied to a propargylic system for the formation of highly 
functionalized allenamides.  
 
 
Figure I-7. Amphipathic heterocycles that can be synthesized from an allenamide 
precursor.  By varying the substrates on the allenamide and its reaction partners, a variety 
of highly functionalized heterocycles can be formed.  These molecules could be screened 
for their ability to modulate transcription. 
 
 
E.2. The Use of Small Molecules as Probes for Gaining Insight into 
Transcription 
 
Small molecules such as the types that can be formed from allenamides can be 
used as probes for perturbing TAD·co-activator interactions.  By preventing co-factors 
from interacting with their endogenous binding partners, small molecules can allow for 
the dissection of the role(s) that individual proteins play in complex events.  Additionally, 
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small molecule ligands that bind specific co-factors can be useful in determining if these 
co-factors are associated with specific cellular phenotypes that are linked to disease states.  
Some small molecule probes that perturb the binding of specific co-factors have already 
been discovered. 
  
E.2.A. Small Molecules that Bind CBP/p300 
 
One type of small molecule that has been shown to bind CBP is an amphipathic 
isoxazolidine that was developed by the Mapp laboratories.
69
  This small molecule was 
first identified as an artificial activator of transcription; however, it was discovered that 
when not linked to a DNA binding moiety, it can function as a transcriptional 
inhibitor.
70,71,72
  When not linked to a DNA binding moiety, the amphipathic 
isoxazolidine has been used to inhibit transcription of two endogenous CBP-KIX ligands 
(MLL and c-Jun) in a luciferase reporter system.
72
  NMR data showing that the 
isoxazolidine binds to the same site on the KIX domain as these transcription factors 
indicates that this small molecule is likely competing with MLL and Jun for binding the 
KIX domain.
69
   
Another small molecule that inhibits the binding to the KIX domain of CBP was 
discovered by the Montminy laboratories from an NMR-based screen.  This screen 
identified a small molecule (KG-501) that is able to inhibit the interaction of CBP and 
one of its endogenous ligands (CREB) in cellulo.
73
  A derivative of KG-501, naphthol 





The binding of transcription factors to the CH1 domain of CBP/p300 has also 
proven to be a target for small molecule inhibition.  Kung and co-workers discovered a 
dimeric epipolythiodiketopiperazine (ETP), chetomin, which is capable binding to the 
CH1 domain of p300 (Figure I-8b).
75
  More recently, the Olenyuk laboratories have 





Figure I-8. Small probes for studying transcription.  a) Small molecules that bind the 
CBP-KIX domain.  b) Small molecules that bind the CBP-CH1 domain.  c) Small 





E.2.B. Small Molecules that Interact with Med23 
 
Med23 (Sur2) is another co-factor found in mammalian cells.  There is evidence 
that the transcriptional activator ESX binds Med23 and in doing so, up-regulates 
expression of the ErbB2 (Her2) gene.  ErbB2 is an important therapeutic target as over-
expression of this protein is seen in approximately 20-30% of breast cancers.
78
  To date, 
there have been few examples of small molecules capable of inhibiting the ESX·Med23 
interaction. One example, from the Mapp laboratories, is a modified version of the 
amphipathic isoxazolidine previously discussed.  Cells treated with this isoxazolidine, 
which contains a biphenyl group attached to the isoxazolidine nitrogen, display a 
significant decrease in ErbB2 mRNA levels relative to vehicle control (Figure I-8c).
79
  
Additionally, wrenchnolol and a related compound, adamanolol have been shown to 
inhibit the binding of ESX to Med23 (Figure I-8c).
74,80  
  
E.2.C. Implications of Using Small Molecules as Tools for Probing the  
Roles of Proteins Involved in Transcription 
 
 
These small molecules serve as valuable tools for probing the relation between 
activators and their target co-activators.  Small molecules that bind to specific domains of 
co-factors such as CBP/p300 are a valuable tool for studying transcription.  Small 
molecule probes such as those described above can effectively inhibit binding of 
endogenous transcription activators to their co-factors.  By employing small molecules 
such as the ones discussed, the roles of specific domains of specific co-factors can 
effectively be studied for a variety of transcription events.  Work presented in hapter 3 of 
this thesis will address the use of synthetic probes that bind the KIX and CH1 domains of 
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p300 in studying the roles of p300 in maintaining pluripotency and self-renewal in cancer 
initiating cells. 
  
F. Thesis Summary 
 
 As seen, there are some known examples of small molecules that alter 
transcriptional events.  While these small molecules have shown promise as probes for 
understanding transcriptional processes, they only modify a small subset of protein-
protein interactions involved in transcription.  Because different protein classes require 
different types of small molecule modulators, it is essential to create diverse small 
molecule libraries that could be used to modulate a variety of different functions.
81
  As 
the synthesis of large libraries can be expensive and time consuming, employing common 
substrates in early stages of synthesis that can be diversified at later points decreases the 
length of syntheses without decreasing the diversity of the final library.  Synthetic 
strategies for forming substrates that can be easily taken on to form a large number of 
small molecule classes would be highly valuable in this endeavor.  As such, Chapter 2 
addresses the development of a novel synthetic strategy for forming fully protected 
allenamides.  As allenamides are pre-cursors in the formation of a wide range of small 
heterocycles, they could serve as a valuable tool in library synthesis.  The work 
accomplished in this study reveals a straight-forward approach to forming highly 
functionalized allenamides from commonly available starting materials.  These 
allenamides can be used as substrates in further transformations and display a different 
reactivity pattern than previously identified allenamides.  Thus, the fully protected 
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allenamides described in this chapter could be used in the formation of a wide range of 
small molecules.   
 The work presented in Chapter 3 highlights the importance of using small 
molecules as probes for studying transcriptional processes.  This chapter centers on 
understanding the roles of CBP and p300 in maintaining pluripotency and self-renewal in 
cancer initiating cells (CICs).  RNAi and small molecule studies were carried out to 
determine if CBP and p300 interacted with key transcription factors that have been 
implicated in maintaining pluripotency and self-renewal.  Preliminary results indicate that 
small molecules that are known to bind to the KIX and CH1 domains of CBP/p300 can 
affect the transcriptional output of a Nanog-driven luciferase reporter.  Additional studies 
indicate that Nanog shows at least some dependency on p300, but not CBP, for 
transcription.  Finally, it has been shown that the amphipathic isoxazolidine selectively 
decreases the population of cancer initiating cells over bulk tumor cells, suggesting that 
perturbing transcription could prove to be a good strategy in designing therapeutics that 
target CICs. 
 The Appendix of this document gives one further example of a small molecule 
scaffold that can modulate transcription.  Presented here is a focused library of small 
molecules based on the common spirooxindole scaffold.  In cellulo studies reveal a subset 
of this library that inhibits the activation of HIF-1α in a luciferase reporter assay.  It was 
also found that these molecules inhibit the activation of a variety of transcriptional 
activators that bind to diverse partners in the transcriptional machinery.  These small 
molecules could be used in the future as general inhibitors of CBP/p300 functionality. 
 24 
 Finally, Chapter 4 takes a step back from transcription and addresses a topic that 
concerns all scientists: research ethics.  In this chapter, the development and 
implementation of a practical research ethics course is discussed.  This course derives 
both its novelty and its utility from the fact that it is designed and taught almost 
exclusively by senior graduate students and is presented to incoming graduate students at 
the start of their first year of graduate school.  Student evaluations and reactions from the 
broader chemical community indicate that this course serves as a valuable addition to the 
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 Allenamides are used as substrates in the synthesis of a variety of different 
compounds, including many highly substituted heterocycles.  As part of our ongoing 
quest to identify small molecule ligands for transcription proteins, we are interested in 
synthesizing a variety of highly substituted cyclic small molecules.  This interest initially 
led us to examine the feasibility of using allenamides as a common substrate to build a 
diverse library of small molecules.  When examining the known routes to allenamide 
formation, we found that these routes were often lengthy and synthetically challenging. 
 It was envisioned that a more effective route toward allenamide synthesis could 
be developed.  Accordingly, a methodology for the straightforward synthesis of highly 
substituted allenamides was developed.  This system relies on a palladium-catalyzed 
phosphorimidate to phosphoramidate rearrangement.  The phosphorimidate can be 
readily synthesized from a propargylic alcohol, a chlorophosphite and a Cbz-azide.  The 
subsequent rearrangement generates allenamides in good yields.  By varying the 
substitution patterns of the propargylic alcohol, mono-, di- and tri-substituted allenamides 
                                                 
a 
Portions of the chapter are reported in Danowitz, A.M.; Taylor, C.E.; Shrikian, T.M.; Mapp, A.K.  A 
Palladium-Catalyzed [3,3]-Rearrangement for the Facile Synthesis of Allenamides . Org. Lett., 2010, 12, 
2574-2577. 
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can be formed.  Additionally, use of an enantiomerically enriched propargylic alcohol, 




B.1. Synthesis of Building Block Molecules that can be used in the Formation 
of Synthetic Probes of Transcriptional Processes 
 
 One of the goals of our laboratory is the design and synthesis of novel ligands for 
transcription co-factors that can act as a tool for studying transcription.  As many 
transcriptional activator proteins exhibit a multi-partner binding profile and bind to their 
co-factors in the transcriptional machinery with moderate affinity, it is likely that a wide 
variety of synthetic scaffolds will be needed to modulate individual binding events.
1,2
    
Therefore, we have an ongoing interest in developing straightforward strategies for the 
synthesis of building block molecules that can be further modified to form structures, 
such as amphipathic heterocycles, which can mimic the functionality of endogenous 
activators and bind to co-factors within the transcriptional machinery.  The allenamide 
scaffold is ideal for this purpose as it has been used as a substrate in the synthesis of a 
wide variety of highly substituted amphipathic heterocycles (Figure II-1).   
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Figure II-1. Small molecule building blocks for the formation of amphipathic 
heterocycles.  The structures shown on the left are building blocks that have been shown 
to undergo further transformations to form heterocycles such as those shown on the right.  
By varying the substituents on the building blocks and their reaction partners, a variety of 
amphipathic heterocycles could be formed.  The allenamide (top left in a box) has been 
shown to form all of the classes of heterocycles shown on the right.  It is therefore a 
promising precursor molecule for the synthesis of libraries of amphipathic heterocyclic 
compounds. 
  
B.2. Allenamides as Substrates for the Formation of Cyclic Small Molecules 
 
 Allenes, or 1,2-dienes, have the ability to act as either nucleophiles or 
electrophiles, thus allowing for their use in the preparation of a variety of synthetic 
precursors or end products.
3,4  
 The reactivity pattern of the allene is heavily influenced by 
heteroatoms that are appended to the allenic system. One such example is the allenamine, 
an allene with a nitrogen atom appended directly to the allenic system.  As the lone 
electron pairs on the nitrogen can be donated into the diene system, allenamines react 
with electrophiles and nucleophiles in a highly regioselective manner.
5
  This electron rich 
nature, however, leads to allenamines being generally unstable compounds that are highly 
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subject to degradation.  Allenamides are analogous structures to allenamines with a 
similar reactivity pattern; however, as the amide moiety has less electron donating 




Figure II-2 Nitrogen substituted allenes.  Top:  Structures of an allene, an allenamine and 
an allenamide are shown.  Bottom: The electronic distribution in the allenic moiety of a 
nitrogen substituted allene is shown.  The electron pair donated by the nitrogen allows 
allenamines and allenamides to react with nucleophiles and electrophiles in a highly 
regioselective manner. 
            
Because of their unique electronic characters, allenamides are used in the 
synthesis of a variety of interesting cyclic compounds.  For example, they have been used 













   It is 
therefore possible that allenamides could be used as a general precursor in the synthesis 
of highly diverse small molecule libraries that could be screened for their effectiveness at 
modulating transcription.   
 
 B.3. Established Routes for Accessing Allenamides 
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 There are a variety of known routes for synthesizing allenamides.  These routes, 
however, often require complex and lengthy substrate synthesis, with the formation of 
enantioenriched allenamides posing a particular challenge.
5,14-21
 One popular route for the 
formation of allenamides involves the iterative addition of functionality to a mono-
substituted allenamide.  This allenamide is formed by base-catalyzed isomerization of a 
propargylic amide to allenamide.  Alkyl functionality can then be appended to this mono-
substituted allenamide in a stepwise fashion.  In this methodology, stereocontrol can only 
be obtained with a chiral auxiliary
5
 (Figure II-3).   
 
Figure II-3. Base-catalyzed isomerization of a propargylic amide to form an allenamide.  
While this is the most commonly used method for forming allenamides, it requires a 
chiral auxiliary to impart stereocontrol and heavily substituted allenamides must be 
formed by iterative addition of functionality to a mono-substituted allenamide.  
 
 In addition to the base-catalyzed isomerization, several metal-catalyzed reactions 





laboratories have demonstrated the utility of a copper-catalyzed coupling of allenyl 
halides to amides in forming allenamides (Figure II-4).  The primary drawback to this 
methodology is the use of allenyl halides which tend to be difficult to synthesize and 
handle, especially in enantiopure form.  As the stereochemistry of the product allenamide 
is set by that of the allenyl halide, this is a sub-optimal route for forming highly 
enantiomerically enriched allenamides.  
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Figure II-4. Example of copper-catalyzed coupling of an allenyl halide with an amide to 
form an allenamide. 
 
 
Another method for the formation of allenamides is a [2,3]-rearrangement of 
propargylic sulfides.
20,21,22 
  This method allows for the predictable transfer of 
stereochemistry to the allenamide.  However, the preparation of propargylic sulfides, 
especially enantioenriched versions, requires several difficult synthetic manipulations 
(Figure II-5). 
 
         
Figure II-5. Examples of [2,3]-sigmatropic rearrangements of propargylic sulfides to 
form allenamides. 
 
 Finally, there have been limited examples of the use of [3,3]-rearrangements to 
form allenamides.
23,24,25,26
 One especially intriguing route for the formation of 
allenamides was reported by Overman and co-workers in the 1970s.
23,24
  This route 
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featured the rearrangement of propargylic tricholoracetimidates to form allenamides.  
While the use of this [3,3]-rearrangement is intriguing, these reactions proceeded in poor 
(10-20%) yields (Figure II-6).  These compounds were mainly synthesized as 
intermediates in the formation of 1,3-dienes and the properties and scope of this 
rearrangement were not fully explored. 
 
Figure II-6. Rearrangement of tricholoacetimidates to form allenamides.  These 
allenamides readily isomerize to 1,3-dienees. 
 
 
 B.4. A Novel Methodology for the Formation of Allenamides  
 
 Upon examining these reactions, it was noted that a [3,3]-rearrangement had the 
potential to circumvent many of the difficulties associated with the other methods of 
allenamide formation. We postulated that a known allylic phosphorimidate to 
phosphoramidate rearrangement could be extended to the formation of allenamides from 
propargylic alcohols.
27,28,29
   The envisioned reaction pathway would rely on three readily 
available starting materials: a propargylic alcohol, a protected azide and a chlorophospite 
(Figure II-7).  In a one-pot procedure, the propargylic alcohol could be reacted with the 
chlorophosphite to form a trivalent phosphorous species that could then undergo a 
Staudinger reduction with the azide for form a phosphorimidate.  This phosphorimidate 
could then undergo a thermal or transition-metal catalyzed rearrangement to form the 
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allenamide product.  It is also postulated that if a chiral propargylic alcohol is employed 
in this reaction, the stereochemical information should carry through to the allenamide.  
If successful, this methodology would allow for the synthesis of highly enantioenriched 
allenamides in a small number of straightforward synthetic steps.   
 
Figure II-7. Novel methodology for the formation of allenamides. Top: Proposed 
reaction pathway for a phosphorimidate to phosphoramidate rearrangement to form 
allenamides.  Bottom: Known allylic phosphorimidate to phosphoramidate rearrangement. 
 
 
C. Optimization Studies 
 
 
 In testing the hypothesis that this rearrangement could be applied to a propargylic 
system, the protecting group, substituents on the phosphorous, use of thermal versus 
metal-catalyzed conditions, and the solvent concentration were varied.   
 
 C.1. Optimization of the Protecting Group 
 
Using propargyl alcohol as the initial substrate, the protecting group used in the 
rearrangement was the first variable examined.   It was found that when either a Cbz or 
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tosyl (Ts) protecting group was appended to the azide in combination with a palladium 
catalyst, we formed the desired allenamide (Table II-1 entries 2-11).  It was also found 
that the Cbz protecting group afforded higher yields over the tosyl group when the 
reactions were run under the same conditions (Table II-1, entires 3 and 7).  Attempts at 
using a benzyl protecting group resulted in no allenamide formation (Table II-1, entry 1).  
Upon closer inspection, it was discovered that the phosphorimidate was not forming from 
the trivalent phosphorous species formed during the first step of this reaction. 
 
C.2. Optimizing the Phosphorous Substituents 
 
As shown in Table II-1, initial attempts were carried out using the cyclic ether 
substituent on the phosphorous that had been most effective in the allylic 
rearrangement.
27,28
  It was postulated that an increased yield of allenamide could be 
achieved by changing to either amine or hydrocarbon substituents.  However, when using 
either diethyl-amino or phenyl groups in this position, no allenamide was formed (Table 
II-1, Entries 12-13).  As was the case when using the benzyl protecting group, the 
phosphorimidate was not formed.   
 
C.3. Optimizing Temperature and Solvent Conditions 
 
It was initially noted that using dichloromethane (DCM) at room temperature 
gave the highest yields (Table II-1, entries 7 and 10).  Use of toluene in this reaction also 
worked, albeit with a lower yield (Table II-1, entry 8).  Attempts to heat the reaction 
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caused a decrease in yield (TableII-1, entry 6).  Decreasing the concentration of 
phosphorimidate from 0.1 M to 10 µM, led to an increase in yield from 49 to 66% (Table 
II-1, entries 5 and 7).   
This finding indicated that the palladium might be causing the degradation or 
polymerization of the product allenamide.  Additionally, if the reaction was allowed to 
proceed any longer than was necessary to completely deplete the starting material, a 
decrease in yield was observed. 
 
C.4. Optimizing for Steric Considerations 
 
The final point of examination in the initial optimization studies was the degree of 
substitution of the alcohol substrate.  It was found that when using the optimized 
conditions (cyclic ether substituents on the phosphorous, Cbz-azide, 10µM DCM at room 
temperature) allenamides were formed in good yields using either a primary or secondary 
propargylic alcohol (Table II-1, Entries 7 and 10).  When tertiary alcohols were used as 
the substrate no allenamide products were formed.  Once again, this was because the 













Entry R1 R2 R3 PG Catalyst Solvent T (°C) Conc %yield 
1 H H  Bn None Xylenes 120 0.1M 0* 
2 H H “  “ Ts None Xylenes 120 0.1M 0 
3 H H “  “ Ts PdCl2(CH3CN)2 DCM RT 0.1M 35 
II-2a 
4 H H “  “ Ts PdCl2(CH3CN)2 DCM 35 0.1M 35 
II-2a 
5 H H “  “ Cbz PdCl2(CH3CN)2 DCM RT 0.1M 49 
II-2b 
6 H H “  “ Cbz PdCl2(CH3CN)2 Toluene 100 0.1M 16 
II-2b 
7 H H “  “ Cbz PdCl2(CH3CN)2 DCM RT 10µM 66 
II-2b 
8 H H “  “ Cbz PdCl2(CH3CN)2 Toluene RT 10µM 58 
II-2b 
9 H H “  “ Cbz PdCl2(CH3CN)2 DCM RT 5 µM 36 
II-2b 
10 H Me “  “ Cbz PdCl2(CH3CN)2 DCM RT 10µM 60 
II-2c 
11 Me Me “  “ Cbz PdCl2(CH3CN)2 DCM RT 10µM 0* 
12 H H (NEt2)2 Cbz PdCl2(CH3CN)2 DCM RT 10µM 0* 
13 H H Ph Cbz PdCl2(CH3CN)2 DCM RT 10µM 0* 
* Phosphorimidate is not formed 
 
 
D. Discovery of a Competing Reaction Pathway 
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 The conditions that resulted in a lack of formation of the phosphorimidate were 
initially intriguing.  It was postulated that a [2,3]-rearrangement of the propargylic 
trivalent phosphorous species was occuring.
30
  We believed that during the course of the 
reaction, the trivalent phosphorous species could either undergo the Staudinger reduction 
or this spontaneous [2,3]-rearrangement depending on which reaction was kinetically 
favored (Figure II-8).  Based on the conditions tried in during the initial optimization,  it 
was discovered that formation of the phosphorimidate was favored under the following 
conditions: the Staudinger reduction was rapid (as is the case when using an electron 
withdrawing azide substituent such as Cbz), when an ether was used as the substituent on 
the phosphorous group, and when a primary or secondary alcohol was used.  The 
formation of the phosphorimidate was disfavored under the following conditions: the 
Staudinger reduction was slow (as is the case when using benzyl azide), an amine or 
hydrocarbon substituent was used on the phosphorous, or when a tertiary alcohol was 
used.  This discovery informed the types of substrates that were used in the subsequent 
optimization and reaction scope studies. 
 
Figure II-8. Desired versus undesired reaction pathway.  The trivalent phosphorous 
species could either undergo a Staudinger reduction and proceed via pathway A to the 
formation of the phosphorimidate or it could undergo a spontaneous [2,3]-sigmatropic 
rearrangement to form the allenyl phosphorous species via pathway B.    
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E. Optimization for Application to Internal Alkynes   
 
 The possibility of introducing functionality at the opposite alkyne terminus was 
examined.  Initially,  a substrate with a methyl group appended at this position was used.  
Unfortunately, this reaction resulted in only 16% yield of product allenamide (Table II-2, 
entry 2).  Upon changing the solvent to toluene and heating the reaction to 100 °C, the 
allenamide was obtained in 13% yield (Table II-2, entry 3).  It was postulated that the 
increased steric bulk caused by the methyl at the 3-position was negatively interacting 
with the phosphorous substituents during the transition state.  To mitigate this effect, the 
cyclic ether substituent on the phosphorous was replaced with ethyl ether substituents.  
While the reaction still proceeded in low yields at room temperature (Table II-2, entries 4 
and 5), a 60% yield of allenamide was obtained when the reaction was heated to 100 °C 
(Table II-2, entry 6).  Additionally a 10% increase in yield was obtained when using the 










































































Conditions: 1) propargylic alcohol (1.6 equiv), 1.3 equiv of R2PCl and 1.3 equiv of    
 Et3N in Et2O, 0 °C, 20 min 2) Cbz azide (1.0 equiv), rt, 2 h.  
b
Phosphorimidate (1.0 
 equiv),  PdCl2(CH3CN)2 (3 mol%), solvent to a final concentration of 0.01 M.  
c





F. Defining the Scope of the Rearrangement 
 
 Upon identifying conditions that worked for both internal and terminal alkynes, 
the method was applied to a broader range of propargylic alcohols to better define the 
II-2 II-3 
 46 
scope of this rearrangement.  Of particular utility would be substitution patterns that 
would allow for the formation of di- and tri-substituted allenamides.   
 Secondary propargylic alcohols were first examined as they would produce 
disubstituted allenamides functionalized at the 1 and 3 positions.  As shown in Table II-3 
(entries 2-8), secondary alcohols with both straight chain and branched alkyl subsituents 
are excellent substrates for the rearrangement. Tertiary propargylic alcohols were not, 
however, good substrates for the reaction as the intermediate propargylic phosphite 
underwent rapid conversion to the corresponding allenyl phosphonate.
30
 
 1,1-Disubstituted allenamides can also be prepared via rearrangement of internal 
alkynes. Alkyl groups are well-tolerated at this position (Table II-3, entries 9 and 10).  
Appending aryl groups at this postion, however, proved to be more challenging.  Primary 
alcohols with less electron-rich aryl substituents were able to react under these 
conditions, albeit with a decrease in yield relative to their alkyl counterparts (Table II-3 
entry 11).  The phosphorimidates formed from secondary alcohols or alcohols with 
electron donating aryl substituents decomposed rapidly, making these alcholos unsuitable 
substrates for this rearrangement (Table II-3 entries 11 and12).    
Tri-substituted allenamides can also be prepared through the reaction of more 
substituted propargylic alcohols (Table II-3, 13 and 14). Tri-substituted allenamides such 
as these would be of particular use as substrates in further synthetic transformations, such 
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R1=H, R2=H 45% a 
R1=Cl, R2=H 27% b 










R1=H, R2=H a 
R1=OMe, R2=H b 





 II-24 II-25 
60% 
a
Conditions as described in Table 1.  
b
Isolated yields.  
c
ee of commercially available 
starting alcohol found to be <95% in each case.
 d 




G. Defining the Stereoselectivity of the Rearrangement 
 
 As was mentioned earlier, the synthesis of enantiomerically enriched allenamides 
is particularly challenging.
5,14-22
  This rearrangement was thus examined for its utility in 
forming enantiomerically enriched allenamides.  It was envisioned that stereochemical 
information could be imparted by using an enantiomerically enriched propargylic alcohol 
as the initial reaction substrate.  Enantiomerically enriched propargylic alcohols are both 
 49 
commercially available and easily synthesized.
31-33   
For this study, three commercially 
available propargylic alcohols were employed.  Either enantiomer of the allenamide 
derived from 3-butyn-2-ol can be readily prepared, both in 92% ee (Table II-3, entries 3 
and 4).  Additionally, an enantiomerically enriched allenamide derived from (R)-(+)-1-
octyn-3-ol was also prepared in 80% ee (Table II-3, entry 8).  The indicated 




Upon further investigation, it was determined that the attenuated enantiopurity is 
due to a Pd-catalyzed epimerization step that the allenamides undergo.  When the 
allenamide derived from (R)-(+)-1-octyn-3-ol was re-subjected to reaction conditions 
(toluene, palladium, heating to 100 °C), a sharp decrease in enantiopurity occurred.  The 
enantiopurity decreased from 80% to 51% after re-subjection to reaction conditions for an 
additional five hours (Table II-4).  Allenamides of higher stereochemical purity can be 











Table II-4. Enantiopurity decreases with time exposed to palladium 
 
       
Reaction time (hours) %ee % yield 
5 80 60 
7.5 72 70 
7.5 + 5 additional  
(12.5 total) 
51 80% recovered 
 
 
H. Utilizing Allenamides as Substrates in Further Reactions 
 
 Despite their utility in a variety of reactions, the lability of nitrogen-substituted 
allenes is a recurring concern.
2-5  
 The fully protected allenamides produced in the 
phosphorimidate rearrangement exhibit considerable stability, and can be stored neat at  
0 °C for over two months with little decomposition.  In comparison, other allenamides 
have been reported to have limited stability when stored neat at -20 °C.
16
  It is postulated 
that the remarkable stability of these allenamides is due to the two electron-withdrawing 
protecting groups on the nitrogen.  By depleting the electron density in the allenic system 
these groups cause a reduction in the reactivity of the allenes.  
 The lack of electron density in the allene system has interesting implications for 
using these allenamides as substrates in further reactions.  With electron rich allenamides, 
II-16 II-15 
 51 
the lone electron pair on the nitrogen can donate into its adjacent double bond, thus 
raising the energy of its HOMO and LUMO.  This activated double bond is then poised 
for 1,3-dipolar cycloadditions and inverse-demand Diels Alder reactions as the higher 
energy HOMO is closer in energy to the LUMO of the binding pair.  This allows for a 
distinct reactivity pattern between the two cumulated double bonds in the allene system.  
An electron-neutral allenic system, such as a hydrocarbon allene, has a different 
reactivity pattern.  In this case, the HOMOs and the LUMOs of both double bonds are 
relatively low in energy.  Thus, these bonds are both poised to undergo Diels-Alder and 
other reactions where their LUMO will react with the HOMO of the binding partner.  As 
the two allenic double bonds are electronically identical, steric considerations tend to 
determine the relative reactivity of the two olefins.
3,4 
The fully-protected allenamides were unreactive towards a variety of reactions 
that other, more electron rich allenamides have been shown to engage in.  For example, 
these allenamides failed to undergo a cycloaddition reaction with methyl vinyl ketone to 
form a pyranyl heterocycle.  They also failed to produce an isoxazoline when reacted 
under the conditions reported by the Zecchi lab on a more electron rich allenamide.
10
  
Finally, they were unable to undergo an acid-or thermal catalyzed rearrangment to form a 
1,3-diene as reported by the Hsung lab for their allenamides.
34 
These allenamides displayed a reactivity pattern more similar to electron neutral 
allenes than to other allenamides.  For example, allenamide II-2f readily undergoes a 
Diels-Alder reaction to produce enamide II-26 (Figure II-8). Using conditions similar to 
those reported for use with allenes,
35
 allenamide II-2f can also be converted to a densely 




our knowledge, this is the first reported example of this reaction using an allenamide 
(Figure II-9).  Both the types and regioselectivity of these reactions indicate that these 




Figure II-9. Applications of fully-protected allenamides. Top: Diels-Alder reaction.  
Bottom: Formation of boron-substituted enamide.  See section I for experimental details.   
 
I. Experimental Methods and Data 
 
Unless otherwise noted, starting materials were obtained from commercial 
suppliers and used without further purification.  DCM, Et2O, and toluene were dried by 
passage though activated alumina columns and degassed by stirring under a dry nitrogen 
atmosphere.  Purification by flash chromatography was carried out with E. Merck Silica 
Gel 60 (230-400 mesh) according to the procedure of Still, Kahn, and Mitra.
38
  All 
reactions involving air- or moisture-sensitive compounds were performed under a 
nitrogen atmosphere.  Cbz azide,
39
 3-Phenylprop-2-yn-1-ol, 3-(4-chlorophenyl)prop-2-















C NMR spectra were recorded in CDCl3 at 400 or 500 
MHz and 125 MHz.  IR spectra were measured as thin films on NaCl plates.   
 
General procedure for allenamide preparation via rearrangement:  
 
To Et2O (10 mL) cooled in an ice/H2O bath was added the propargylic alcohol 
(1.3 mmol, 1.6 eq) and Et3N (1.0 mmol, 1.3 eq), followed by dropwise addition of diethyl 
chlorophosphite (1.0 mmol, 1.3 eq).  The solution was allowed to stir for 20 min and the 
precipitated Et3N·HCl was removed by filtration.  The Et2O was removed under vacuum 
and the residue dissolved in 1.7 mL DCM.  Cbz azide (0.77 mmol, 1.0 eq) was added 
dropwise at RT.  The reaction was then allowed to stir for 2 h.  The DCM was removed 
under vacuum and the crude mixture was subjected to flash chromatography (gradient 1:5 
hexanes/EtOAc to 1:2.5 hexanes/EtOAc).  The phosphorimidate decomposed upon 
standing and was thus used immediately upon isolation. 
 To a solution of DCM (20 mL) was added the phosphorimidate (0.2 mmol, 1.0 eq) 
and 3 mol% PdCl2(CH3CN)2.  The reaction was stirred at room temperature with 
monitoring by TLC (1:1 hexanes/EtOAc) for 5-7h, at which time starting material was no 
longer present.  The DCM was then removed under vacuum and the crude mixture was 
immediately subjected to flash chromatography (1:5 hexanes/EtOAc to 1:2.5 
hexanes/EtOAc to 1:1 hexanes/EtOAc) to provide the product allenamide.  Note that 







Benzyl diethoxyphosphoryl(propa-1,2-dienyl)carbamate (II-2f): Prepared via the 
general procedure  in 76% yield (57 mg) from the corresponding phosphorimidate (82% 
yield) as a colorless oil. 
1
H NMR: δ 1.27 (t, J = 6.6 Hz, 6H), 4.00-4.15 (m, 4H), 5.19 (dd, 
J = 3.5, 6.3 Hz, 2H), 5.22 (s, 2H), 6.33 (dd, J = 6.4, 13.3 Hz, 1H), 7.29-7.39 (m, 5H); 
13
C 
NMR: δ 15.93 (d, J = 8.6 Hz), 64.19 (d, J = 7.6 Hz), 68.6, 83.6, 95.6, 135.1, 153.4, (d, J 
= 9.5 Hz), 206.4 (d, J = 5.8 Hz); IR (film): 2984, 1731, 1455, 1441, 1383, 1283, 1026 cm
-
1
; HRMS (ESI) calcd for [C15H20NO5P+Na]
+












Benzyl buta-1,2-dienyl(diethoxyphosphoryl)carbamate (II-4):  Prepared via the 
general procedure in 68% yield (44 mg) from the corresponding phosphorimidate (71% 
yield) as a colorless oil.  
1
H NMR: δ 1.29 (t, J = 7.5 Hz, 6H), 1.72 (dd, J = 2.5, 7.2 Hz, 
3H), 4.08-4.22 (m, 4H), 5.25 (s, 2H), 5.57-5.60 (m, 1H), 6.22- 6.24 (m, 1H), 7.33-7.42 
(m, 5H); 
13
C NMR δ: 14.3 (d, J = 2.0 Hz), 16.0 (d, J = 3.4 Hz), 64.1 (d, J = 3.4 Hz), 64.1 
(d, J = 3.4), 68.5, 94.6 (d, J = 3.4 Hz), 94.9, 128.2, 128.4, 128.5, 135.3, 153.7 (d, J = 9.6 
 55 
Hz), 202.1 (d, J = 5.4 Hz); IR (film): 2984, 1728, 1456, 1381, 1276, 1024 cm
-1
; HRMS 
(ESI) calcd for [C16H22NO5P+Na]
+





(S)-Benzyl buta-1,2-dien-1-yl(diethoxyphosphoryl)carbamate (II-8): Prepared via the 
general procedure in 70% yield from the corresponding phosphorimidate (56% yield) as a 




C data identical to that outlined for compound II-4 [α]D
23
= -53.7 
(c = 1, CH2Cl2) .  92% ee (Chiral HPLC Chiralcel OJ column, flow rate 1 mL/min, 0.4 % 






(R)-Benzyl buta-1,2-dien-1-yl(diethoxyphosphoryl)carbamate (II-6): Prepared via the 
general procedure in 67% yield from the corresponding phosphorimidate (72% yield) as a 




C data identical to that outlined for compound II-4.  92% ee 
(Chiral HPLC Chiralcel OJ column, flow rate 1 mL/min, 0.4 % hexanes in IPA, detected 






Benzyl diethoxyphosphoryl(penta-1,2-dienyl)carbamate (II-10): Prepared via the 
general procedure in 68% yield (54 mg) from the corresponding phosphorimidate (25% 
yield) as a pale yellow oil.  
1
H NMR: δ 1.01 (t, J = 7.0 Hz, 3H), 1.27 (t, J = 7.0 Hz, 6H), 
2.03-2.10 (m, 2H), 4.04-4.21 (m, 4H), 5.22 (s, 2H), 5.59-5.65 (m, 1H), 6.22-6.26 (m, 2H), 
7.30-7.41 ( m, 5H); 
13
C NMR: δ 12.9, 16.0 (d, J = 6.9 Hz), 22.2 (d, J = 1.5 Hz), 64.0 (d, J 
= 6.1 Hz), 68.4, 95.5 (d, J = 2.3 Hz), 101.6, 128.1, 128.3, 128.4, 135.3, 153.7  (d, J = 7.7 
Hz),  201.0 (d, J = 4.6 Hz); IR (film): 2967, 1728, 1380, 1278 1024 cm
-1
; HRMS (ESI) 
calcd for [C17H24NO5P+Na]
+





Benzyl diethoxyphosphoryl(octa-1,2-dien-1-yl)carbamate (II-14): Prepared via the 
general procedure in 70% yield (55 mg) from the corresponding phosphorimidate (67% 
yield) as a pale yellow oil.  
1
H NMR: δ 0.86 (t, J = 7.2 Hz, 3H), 1.22-1.30 (m, 10H), 1.40 
(m, 2H), 2.04 (m, 2 H), 4.02-4.21 (m, 4H), 5.21 (s, 1H), 5.53-5.59 (m, 1H), 6.18-6.22 (m, 
1H), 7.30-7.40 (m, 5H); 
13
C NMR: δ 14.0, 16.0 (d, J = 8.8 Hz), 22.4, 28.4, 28.8 (d, J = 
1.3 Hz), 31.3, 64.1 (d, J = 7.3 Hz), 68.4, 95.0 (d, J = 3.4 Hz), 100.1, 128.1, 128.3, 128.5, 




; HRMS (ESI) calcd for [C20H24NO5P+Na]
+






(S)-Benzyl diethoxyphosphoryl(octa-1,2-dien-1-yl)carbamate (II-16):  Prepared via 
the general procedure in 70% yield (44 mg) from the corresponding phosphorimidate 




C data identical to that outlined for compound 
II-12. [α]D
23
= -50.9 (c = 1 CH2Cl2).  80% ee (Chiral HPLC Chiralcel OJ column, flow 
rate 1 mL/min, 0.3% hexanes in IPA, detected at 254 nm. Rt = 10.97 (maj), 12.68 (min).  
The yield increased with extended reaction times but epimerization was observed.  See 





Benzyl diethoxyphosphoryl(4-methylhepta-1,2-dienyl)carbamate (II-12):  Prepared 
via the general procedure, with the exception that the rearrangement took 12 h for 
depletion of starting material, in 65% yield (51 mg) from the corresponding 
phosphorimidate (77% yield) as a pale yellow oil.  The reported product is a mixture of 2 




H NMR: δ 0.86 (t, J = 6.8 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H) 1.22-1.36 (m, 8H), 
2.19-2.28 (m, 1H), 4.05-4.21 (m, 4H), 5.22 (s, 1H), 5.48-5.55 (m, 1H), 6.22 (dt, J = 2.6, 
6.2 Hz, 1H), 7.30-7.41 (m, 5H); 
13
C NMR: δ 14.0, 14.1, 15.9, 16.0, 19.8, 19.9, 20.2, 33.5 
(d, J = 1.4 Hz), 33.7, 38.3, 38.9, 64.0 (d, J =  6.3 Hz), 64.0 (d, J = 4.8 Hz), 68.4, 95.5 (d, 
J = 3.3 Hz), 95.6 (d, J = 3.4 Hz) 105.7, 105.8, 128.1, 128.2, 128.4, 135.3, 153.7 (d, J = 
10.0 Hz), 200.4 (d, J = 4.6 Hz); IR (film): 2958, 1731, 1456, 1379, 1275, 1026 cm
-1
; 
HRMS (ESI) calcd for [C20H24NO5P+Na]
+











Benzyl buta-2,3-dien-2-yl(diethoxyphosphoryl)carbamate (II-2e): Prepared as stated, 
with the exception that the rearrangement was carried out in toluene at 100 °C for 12h on 
a 0.6 mmol scale (0.23 g phosphorimidate), in 58% yield (125 mg) from the 
corresponding phosphorimidate (75% yield) as a pale yellow oil.  
1
H NMR: δ 1.28 (dt, J 
= 0.8, 7.0, 6H), 1.28 (t, J = 7.0 3H), 1.99 (dt, J = 1.2, 3.1 Hz 3H), 4.04-4.22 (m, 4H), 
5.00-5.04 (m, 2H), 5.22 (s, 2H), 7.32-7.40 (m, 5H); 
13
C NMR: δ 16.0 (d, J = 6.9 Hz), 
19.7, 64.0 (d, J = 5.4 Hz), 68.2, 80.0 (d, J = 2.3 Hz), 105.0, 127.9, 128.2, 128.5, 135.5, 
153.7 (d, J = 9.2 Hz), 208.4 (d, J = 4.7 Hz); IR (film): 2983, 1728, 1497, 1455, 1380, 
1271, 1024 cm
-1
;  HRMS (ESI) calcd for [C16H22NO5P+Na]
+






Benzyl diethoxyphosphoryl(penta-1,2-dien-3-yl)carbamate (II-18):  Prepared via the 
general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C, in 58% yield (32.5 mg) from the corresponding phosphorimidate (75% yield) as a 
colorless oil.  
1
H NMR: δ 0.99 (t, J = 7.6 Hz, 3H), 1.25 (dt, J = 0.8, 6.8 Hz, 6H),  2.18-
2.28 (m, 2H) 4.00-4.18 (m, 4H), 5.08-5.11 (m, 2H), 5.18 (s, 2H), 7.30-7.40 (m, 5H); 
13
C 
NMR:  δ  11.0, 16.0 (d, J= 8.8 Hz), 25.7, 64.0 (d, J= 7.3 Hz), 68.2, 82.1 (d, J= 2.4 Hz), 
111.0, 127.8, 128.2, 128.4, 135.5, 153.9 (d, J= 11.6 Hz), 207.7 (d, J= 4.9 Hz); IR (film): 
2977, 1727, 1456, 1380, 1278, 1025 cm
-1
; HRMS (ESI) calcd for [C17H24NO5P+Na]
+
: 





Benzyl diethoxyphosphoryl(hexa-3,4-dien-3-yl)carbamate (II-25): Prepared via the 
general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C on a 0.1 mmol scale (41 mg phosphorimidate), in 60% yield (25 mg) from the 
corresponding phosphorimidate (48% yield) as a yellow oil. 
1
H NMR: δ 0.98 (t, J = 7.4 
Hz, 3H), 1.28 (dt, J = 0.8, 7.2 Hz, 6H), 1.69 (d, J = 5.4 Hz, 3H), 2.21-2.27 (m, 2H), 4.03-




NMR: δ 11.1, 14.1 (d, J = 2.9 Hz), 16.0 (d, J = 7.6 Hz), 26.2, 63.8 (d, J = 3.8 Hz), 63.9 (d, 
J = 3.9 Hz), 68.0, 93.4 (d, J = 2.9 Hz), 110.0, 127.8, 128.1, 128.4, 135.6, 154.0, 203.0 (d, 
J = 4.9 Hz); IR (film): 2978, 1726, 1456, 1378, 1272, 1024 cm
-1
; HRMS (ESI) calcd for 
[C18H26NO5P+Na]
+







Benzyl diethoxyphosphoryl(hexa-2,3-dien-2-yl)carbamate (II-23): Prepared via the 
general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C, in 58% yield (42.5 mg) from the corresponding phosphorimidate (50% yield) as a 
yellow oil.   
1
H NMR: δ 0.99 (t, J = 7.6 Hz, 3H), 1.27 (t, J = 7.2 Hz, 6H), 1.97 (dd, J= 1.2, 
2.8 Hz, 3H), 2.03 (dq, J= 2.4, 8.6 Hz, 2H), 4.04-4.19 (m, 4H), 5.20 (s, 2H), 5.40-5.48 (m, 
1H), 7.30-7.40 (m, 5H); 
13
C NMR: δ 13.1, 16.0 (d J = 9.1 Hz), 20.3, 22.1 (d, J = 3.3 Hz), 
63.5 (d, J= 5.1 Hz), 68.1, 98.2 (d, J= 2.4 Hz), 105.0 (d, J = 1.0 Hz), 128.0, 128.2, 128.4, 
135.5, 153.9 (d, J = 11.9 Hz), 202.7 (d, J = 5.3 Hz); IR (film): 2980, 1728, 1456, 1380, 
1277, 1026cm
-1
; HRMS (ESI) calcd for [C18H26NO5P+Na]
+





Benzyl diethoxyphosphoryl(1-phenylpropa-1,2-dienyl)carbamate (II-20a): Prepared 
via the general procedure, with the exception that the rearrangement was carried out in 
toluene at 100°C on a 0.6 mmol scale, in 41% yield (0.103 g) from the corresponding 
phosphorimidate (68% yield) as an oil.   
1
H NMR: δ 1.25 (t, J = 7.0 Hz, 3H), 1.25 (t, J = 
7.0 Hz, 3H), 4.05-4.13 (m, 2H), 4.15-4.25 (m, 2H), 5.20 (s, 2H), 5.49 (d, J = 5.8 Hz, 2H), 
7.20-7.25 (m, 3H), 7.27-7.30 (m, 3H), 7.33 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 7.4 Hz, 2H); 
13
C NMR: δ 16.0 (d, J = 6.9 Hz), 64.5 (d, J = 6.1 Hz), 68.4, (d, J =1.9 Hz), 83.9 (d, J 
=2.4 Hz), 110.6, 125.1, 127.5,  128.1, 128.3, 128.5, 133.8 (d, J = 1.2 Hz), 135.3, 154.0 (d, 
J = 10.0 Hz), 209.2 (d, J = 3.8 Hz); IR (film): 2982, 1731, 1495, 1491, 1380, 1272, 1024 
cm
-1
; HRMS (ESI) calcd for [C21H24NO5P+Na]
+






20c):  Prepared via the general procedure, with the exception that the rearrangement was 
carried out in toluene at 100°C on a 0.6 mmol scale (0.241 g phosphorimidate), in 25% 
yield (72 mg) from the corresponding phosphorimidate (32% yield) as an oil.  
1
H NMR: δ 
1.24 (t, J = 6.8 Hz, 6H), 3.73 (s, 1H), 4.08-4.13 (m, 2H), 4.13-4.21 (m, 2H), 5.18 (s, 2H), 
5.47 (d, J = 5.6 Hz 2H), 6.76 (d J = 8.4 Hz, 1H), 6.91 (s, 1H), 6.97 (d, J = 7.6 Hz 1H), 
7.19-7.23 (m, 3H), 7.24-7.28 (m, 2H); 
13
C NMR: δ 16.0 (d, J = 8.25 Hz), 55.1, 64.6 (d, J 
 62 
= 6.8 Hz), 68.4, 83.9 (d, J = 2.9 Hz), 110.4, 110.5, 115.4, 117.6, 127.8, 128.1, 128.4, 
129.5, 135.4, 154.1, 159.8, 209.3 (d, J = 4.9 Hz), IR (film): 2980, 1732, 1456, 1379, 1276, 
1024 cm
-1
; HRMS (ESI) calcd for [C22H26NO6P+Na]
+











Benzyl 1-(4-chlorophenyl)propa-1,2-dienyl(diethoxyphosphoryl)carbamate (II-20b):  
Prepared via the general procedure, with the exception that the rearrangement was carried 
out in toluene at 100°C on a 0.3 mmol scale (0.135 g phosphorimidate), in 27% yield (37 
mg) from the corresponding phosphorimidate (77% yield) as an oil.  
1
H NMR: δ 1.25 (t, J 
= 7.2 Hz, 6H), 4.01-4.14 (m, 2H), 4.14-4.24 (m, 2H), 5.19 (s, 2H), 5.50 (d, J = 5.6 Hz, 
2H), 7.21-7.25 (m, 2H), 7.23-7.32 (m, 7H); 
13
C NMR δ: 16.0 (d, J = 7.0 Hz), 64.6 (d, J = 
5.8 Hz), 68.5, 84.3 (d, J = 2.3 Hz), 109.9, 126.3, 127.8, 128.4, 128.7, 132.5, 133.0, 133.3, 
135.2, 153.9 (d, J = 9.7 Hz), 209.1 (d, J = 3.9 Hz); IR (film): 2981, 1732, 1491, 1380, 
1277, 1025 cm 
-1
; HRMS (ESI) calcd for [C21H23ClNO5P+Na]
+
: 458.0900, found: 
458.0886. 





(II-26):  Allenamide (II-2f) (70 mg, 0.22 mmol) was combined with freshly cracked 
cyclopentadiene (0.18 mL, 2.2 mmol) in toluene (0.4 mL) under N2. The reaction was 
sealed and heated to 100º C for 8 hours, after which the toluene was removed under 
reduced pressure and the crude reaction mixture was purified by flash chromatography 
(25-50% ethyl acetate in hexanes) to yield II-26 as a colorless oil (63 mg, 0.16 mmol, 
73%). Configuration determined by 1D NOESY. 
1
H NMR: δ 1.24 (dt, J = 0.4, 6.8 Hz, 
3H), 1.25 (dt, J = 0.8, 6.8 Hz, 3H), 1.41 (d, J = 8.4 Hz, 1H),  1.58 (d, J = 10 Hz,1H),  
1.71-1.75 (m, 1H), 2.16-2.20 (m, 1H), 2.92 (s, 1H), 3.27 (s, 1H),  4.00-4.16 (m, 4H), 
5.12-5.17 (m, 2H), 5.95 (d, J = 2.5 Hz, 1H), 5.99-6.00 (m, 1H), 6.12-6.13 (m, 1H), 7.26-
7.32 (m, 5H); 
13
C NMR: δ 16.03 (d, J = 2.3 Hz), 16.10 (d, J = 2.7), 31.93, 41.42, 48.36, 
50.36,  64.02-64.13 (m), 68.08, 114.1, 127.9, 128.0, 128.2, 128.4, 133.3 (d, J = 1.9), 
135.5, 137.7, 146.8 (d, J = 4.67 Hz), 154.1 (d, J = 10 Hz), IR (film): 3000, 1731, 1455, 
1441, 1383, 1283, 1026 cm
-1
; HRMS (ESI) calcd for [C20H26NO5P+Na]
+
: 414.1446, 
found: 414.1444.  
 
 








dioxaborolan-2-yl)methyl)prop-1-en-1-yl)carbamate (II-27):  To allenamide (II-2f) 
(35 mg, 0.107 mmol) was added bis(pinacolato)diboron (31 mg, 0.12mmol) and 
bis(acetonitrile)dichloropalladium(II) (1.4 mg, 0.0055 mmol), and a stir bar. The flask 
was evacuated and purged with N2 3 times, followed by the addition of toluene (0.44 mL) 
and benzoyl chloride (distilled from calcium chloride, 15 µL, 0.13 mmol). The reaction 
was heated to 80º C under N2 for 6 hrs after which the solvent was removed under 
reduced pressure and the crude reaction was purified by flash chromatography (25-50% 
ethyl acetate in hexanes) to give II-27 as a colorless oil (28 mg, 0.050 mmol, 47%) as an 
inseparable isomeric mixture with (E)-II-27 as the major diastereomer (dr 9:1 as 
determined by 
1
H NMR integration of  the signals at 6.51 and 6.58 ppm).  Configuration 
of major isomer determined by 1D NOESY. 
1
H NMR: δ 1.18 (s, 9H), 1.24 (dt, J = 1, 6 
Hz, 6H), 1.97 (s, 2H),  4.06-4.20 (m, 4H), 5.21 (s, 2H), 6.51-6.52 (m, 1H), 6.58 (m, 1H, Z 
isomer),  7.30-7.39 (m, 7H), 7.44-7.48 (m, 2H), 7.71-7.73 (m, 2H), 8.04-8.06 (m, 2H, Z 
isomer).  
13
C NMR: δ 13.48 (d, J = 6.7 Hz), 16.77, 22.21, 62.08 (d, J = 6.23 Hz), 66.26, 
80.86, 125.5, 125.7, 125.9, 126.0, 126.0, 127.2, 127.6, 129.4, 131.8, 132.5, 135.5, 137.6 
(d, J = 4.8 Hz), 150.3 (d, J = 8.2 Hz), 194.8, IR (film): 2923, 1717, 1685, 1279, 1208, 
1142, 1026 cm
-1
; HRMS (ESI) calcd for [C28H37BNO8P+Na]
+
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Utilizing p300/CBP Ligands to Disrupt Transcription of Genes Governing 





 The cancer initiating cell (CIC) hypothesis is based on the idea that a 
subpopulation of cancer cells are able to initiate tumorigenesis by undergoing self-
renewal and differentiation.  CICs have been found in several types of cancers including 
cancers of the: breast, brain, colon, head and neck, pancreas, skin, liver, lung and ovaries 
and are often associated with poor patient prognosis.  These cells share many biochemical 
pathways with embryonic stem cells (ESCs) including a reliance on key transcription 
factors (Nanog, Sox2 and Oct4) that govern pluripotency and self-renewal.  Evidence 
obtained in ESCs indicates that the co-factor p300 plays a role in Nanog driven gene 
expression; however, no direct evidence has been obtained for this role in CICs.  We 
hypothesize that p300 and/or CBP are required for Nanog-driven gene expression in CICs 
and that disrupting their function will lead to a decrease the ability of CICs to maintain 
pluripotency and self renew.  Here, the roles of CBP and p300 in Nanog-driven gene 
expression are examined through a combination of RNAi knockdowns of CBP and p300 
and through the use of synthetic ligands that target specific domains of p300.  It was 
found that p300 but not CBP was necessary for Nanog- driven gene expression in a 
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luciferase reporter context.  Additionally, it was found that two synthetic ligands that 
target the KIX and CH1 domains of p300 (an amphipathic isoxazolidine and a hydrogen 
bond surrogate respectively) inhibit Nanog-driven gene expression.  It was also 
discovered that the amphipathic isoxazolidine inhibits CIC viability preferentially to bulk 
tumor cells.  These studies are consistent with a model in which p300 is a key protein 
required for Nanog-driven gene expression and that inhibiting its function may provide 
insight into how pluripotency and self-renewal are governed in CICs. 
 
B. Introduction 
B.1. Cancer Initiating Cell (CIC) Model 
  B.1.A. Origins of the Model 
 
The cancer initiating cell (CIC) hypothesis (also referred to as the cancer stem cell 
(CSC) hypothesis) was first proposed in the 1990s by Dick and co-workers.  In these 
studies, it was found that only a small subset of acute myeloid leukemia (AML) cells 
were able to initiate human AML in non-obese diabetic/severely combined 
immunodeficient (NOD/SCID) mice.  These cells were positive for cell surface markers 









). It was therefore postulated that leukemia-initiating 
transformation and progression originated from an aberrant undifferentiated cell which 
then established a hierarchical organization within the cancer whereby only 
undifferentiated, pluripotent cells had the capacity to extensively proliferate and self 
renew (Figure III-1).
1,2
  Subsequent to this work, CICs were identified in a variety of 
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solid tumor cancers including cancers of the: breast, brain, colon, head and neck, 
pancreas, skin, liver, lung and ovaries.
3
 
         
Figure III-1. Cancer initiating cell model.  In this model, only cancer initiating 
cells (purple) are able to proliferate extensively to form new cells.  The daughter cells can 
either become differentiated into bulk tumor cells (blue and red) or be maintained in a 
pluripotent state as a new generation of cancer initiating cells.  
 
 
B.1.B Therapeutic Implications of the CIC Model 
 
Despite advances in cancer treatments, the prognoses of many major cancers 
remain poor.  This effect has traditionally been attributed to incomplete elimination of 
tumor cells, or the re-awakening of “dormant” tumor cells after treatment has ended.  
However, the CIC hypothesis provides a different theory for how tumors can avoid 
elimination from traditional chemotherapeutics; namely that by virtue of having distinct 
cellular processes, CICs are not affected by therapeutics targeted against bulk tumor 
cells.
4
  As traditional chemotherapeutics are targeted against bulk tumor cells, they may 
cause an initial decrease in tumor size; however, the unaffected CICs are able to re-grow 
the original tumor, leading to a re-emergence of the disease (Figure III-2). Understanding 
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the processes that govern pluripotency and self-renewal in CICs is an essential step in the 
development of therapeutics designed to target this cell population.   
CICs from a variety of tumors have been shown to be immune to traditional 
chemotherapeutics and ionizing radiation.
5
  In a recent study by Donahoe and co-workers, 
human ovarian cancers containing a mixed population of bulk tumor and cancer initiating 
cells were treated with various chemotherapeutic eagents.
6
  The relative populations of 
both types of cells were then analyzed using fluorescence activated cell sorting (FACS).  
It was shown that doxorubicin, cisplatinum and paclitaxel—all traditional 
chemotherapeutic agents—reduced the relative population of bulk tumor cells while 
having an insignificant effect on the CIC population.
6 
 
Additionally, in a study of primary breast cancers, Song and co-workers found 
that 74% of cells from patients who had undergone chemotherapy displayed stem cell 
surface markers, whereas only 9% of cells from patients who had not undergone 
chemotherapy displayed these markers.
7
  Similar findings have been reported in 
pancreatic cancer cells.
8
  Evidence such as this indicates that CICs are likely to play an 
important role in cancer initiation and resistance to chemotherapeutics.  As CICs rely on 
a set of transcription factors that govern pluripotency and self-renewal that are largely 
inactive in differentiated cells, it is likely that by targeting the function of these proteins, 
therapeutics that specifically target CICs can be developed.
9


















Figure III-2. Therapeutic paradigm in light of the CIC theory. A tumor consisting of 
CICs (purple) and bulk tumor cells (red, blue, green) is treated by two different 
approaches.  Top: Traditional chemotherapeutics are applied to the tumor, resulting in 
death of the bulk tumor cells and temporary decrease in tumor size; however, the CIC is 
not affected by treatment.  After time, the CIC is able to re-grow the original tumor, 
resulting in a relatively higher percentage of CIC cells versus bulk tumor cells.  Bottom: 
The tumor is treated with an agent capable of eliminating CICs.  The remaining bulk 
tumor cells can then be eradicated with traditional chemotherapeutics resulting in 
degeneration of the tumor. 
 
 
B.2 Transcription in CICs 
 
One difference between differentiated and pluripotent cells is the presence of key 
transcription factors that help maintain pluripotency and self-renewal.  It is likely that 















responsible for bridging DNA-bound transcriptional activators with RNA-Polymerase II) 
for these activators and elucidating the mechanisms by which these partners interact with 
the transcription factors will give insight into how pluripotency and self-renewal are 
maintained.   
Studies comparing gene expression profiles of embryonic stem cells (ESCs) and 
CICs reveal that there are many similarities between the two populations including a 
reliance on a c-Myc-centered regulatory network, and the expression of several 
transcription factors.
 10,11,12,13
  Three of these transcription activators, Oct4, Nanog and 
Sox2, have been found in ESCs to govern pluripotency and self-renewal and it is 
postulated that they many fill the same roles in CICs.
10  
 This finding indicates that 
studies of transcription factors carried out in ESCs may also hold true in CICs and 
therefore give insight into mechanisms for disrupting pluripotency and self-renewal in 
CICs. 
 
B.2.A. The Roles of Nanog, Sox2 and Oct4 in ESCs 
 
In ESCs, it has been found that Oct4, Nanog and Sox2 are key transcription 
factors involved in the maintenance of pluripotency and self-renewal.
14
  A delicate 
balance of Oct4 levels is necessary for maintenance of pluripotency, with both down-
regulation and overexpression of Oct4 in ESCs resulting in differentiation.
15
  Similarly, 
knockdown of Nanog in ESCs causes the cells to lose their ability to self-renew.
16
  
 Mounting evidence suggests that these three factors often work in tandem to 




  A substantial fraction of these genes were found to have binding sites for all 
three of these transcription factors in close proximity in their promoters; indicating that 
these factors may work as a complex to recruit additional members of the transcriptional 
machinery.
17,18,19
  Finally, it has been noted that these factors work together to auto-
regulate expression of their own genes, which may help maintain the optimal level of 
these proteins needed to retain pluripotency.
20
  As the mechanisms by which these 
proteins regulate transcription is not fully understood, elucidating the interactions 
between these proteins and the co-factors they bind will provide a greater understanding 
of how these factors maintain pluripotency and self-renewal, and may provide insight 
into how induce differentiation in CICs.
14 
 
B.3. The Role of CBP/p300 in ESCs    
 
The Creb-bindind protein (CBP) and its paralog p300 are large, multi-domain 
proteins that have acetyltransferase activity and can serve as bridges between DNA-
bound transcriptional activators and the transcriptional machinery.
21,22
  While CBP and 
p300 are highly homologous proteins, they have been shown to have distinct roles in 
several cellular processes.  CBP and p300 have been shown to play a role in the 
transcription of several different genes in differentiated adult cells.
21,22   
Evidence is 
emerging that these co-factors may also play a critical role in the transcription of genes 
associated with pluripotency and self-renewal in stem cell models.     
  A study conducted in embryonal carcinoma cells (a stem cell model system) by 
Kawasaki and co-workers provided early evidence for distinct roles of CBP and p300 in 
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maintenance of pluripotency and self-renewal.  In this study, hammerhead ribozymes 
were designed to specifically knock out CBP or p300 mRNA.  It was discovered that 
cells expressing the p300 specific ribozyme became immune to retinoic-acid induced 
differentiation; however no such effect was observed in the cells expressing CBP specific 
ribozymes.  Additionally, it was found that both CBP and p300 were required for 
retinoic-acid induced apoptosis.
23
  These findings, along with other findings from 
hematopoietic stem cells, indicate that p300 and CBP play distinct and important roles in 
maintaining pluripotency and self-renewal in stem cell systems.
24
 
The mechanisms by which p300 and CBP affect differentiation are not well 
understood.  However, there is evidence that these proteins may play a role in Oct4, 
Nanog and Sox2-mediated transcription (Figure III-3). Chen and co-workers used 
chromatin immunopercipitation coupled with ulta-high-throughput DNA sequencing 
(ChIP-seq) in ESCs to map the locations of Oct4, Nanog and Sox2, and the location of 
p300.  They found that p300 co-occurred with Oct4-Nanog-Sox2 binding clusters, 
suggesting that one or more of these factors were capable of recruiting p300.  
Accordingly, they found that when RNA interference (RNAi) targeted against any of 
these three factors was introduced to the cell, there was a reduction in p300 binding at 
these sites.
25
  Additionally, work carried out in mouse ESCs suggests that p300 aids in 
Nanog-driven gene expression by acetylating a distal regulatory region of the Nanog 
promoter.
26
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Figure III-3.  Schematic of the role of CBP and/or p300 in maintaining pluripotency and 
self-renewal.  Many genes associated with pluripotency and self-renewal have binding 
sites for Oct4, Sox2 and Nanog upstream of their promoters.  Recruitment of CBP and or 
p300 by these factors is a necessary step for the transcription involved in genes governing 
pluripotency and self-renewal. 
 
 
A reliance on p300 for Sox2-mediated transcription has been demonstrated in the 
Rizzino laboratories.  Using chimeric fusion proteins comprised of the Gal4 DBD and the 
Sox2 TAD, they examined the effects of p300 on a Sox2-driven reporter system.  An 
increased level of transcription was observed when p300 was overexpressed in the cell.  
Conversely, they found that when a protein capable of sequestering endogenous p300 
(E1A) was introduced, transcription levels decreased in a dose dependant manner.
27
  
Activator by-pass experiments performed in a follow up study in which p300 was fused 
directly to the Gal4 DBD resulted in increased levels of transcription in a similar reporter 
system.
28
  Additionally, they found that the activity observed in the activator by-pass 
experiments could be decreased when the Sox2 TAD was overexpressed in these cells.
29
 




B.4. Small Molecules that Target CBP/p300  
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As CBP and p300 are important co-factors in regulation transcription of 
differentiated cells, several small molecule and peptidomimetic scaffolds have been 
developed that can inhibit the function of specific domains of these molecules.  These 





An amphipathic isoxazolidine (444) with the ability to modulate transcription was 
discovered by the Mapp laboratories (Figure III-4).
33
  NMR, photocrosslinking and in 
cellulo studies indicate that this molecule acts in part by binding to the KIX domain of 
CBP.
34,35,36
  444 was originally attached to a DNA-binding domain and used to activate 
transcription.
33,34
  It was discovered that when not attached to a DNA binding domain, 
444 could inhibit transcription.
36
  Specifically, 444 was shown to elicit a dose-dependent 
decrease in transcription driven by two natural ligands of the p300/CBP KIX domains, 
MLL and c-JUN.
36
  Data obtained by the Mapp laboratories indicates that 444 can elicit 
biological responses consistent with binding the KIX domain of CBP in a variety of adult 
human cell lines (HeLa, HEK 293T and MCF7).  Additional unpublished data indicates 
that 444 generally does not affect cellular viability, even at high micro-molar doses.  For 
example, 444 has no effect on cellular viability of MCF7 cells at concentrations as high 
as 400µM.  These features make 444 an attractive small molecule probe for studying 
cellular functions that rely on the KIX domain of CBP.   
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Figure III-4. Structure of amphipathic isoxazolidine (444). 
 
Hydrogen Bond Surrogates (HBS) 
A second scaffold that can be used for targeting specific domains of CBP/p300 is 
the hydrogen bond surrogate (HBS) (Figure III-5).  The HBS scaffold overcomes the 
energetic demands necessary for amino acids to form an α-helix by covalently linking the 
i and i+ 4
th
 residue of a peptide sequence such that a preorganized α-turn is formed.
37
  
Recently, the Arora laboratories developed an HBS designed to target the CH1 domain of 
p300.  This HBS, which was modeled on the activation domain of an endogenous CH1 





Figure III-5. Structure of a hydrogen bond surrogate (HBS).  The sequence of the amino 
acid residues included in the HBS that binds the CH1 domain of p300/CBP is given to the 
left.  X denotes a pentenoic acid residue. 
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The HBS is a very versatile scaffold that has also been used to mimic a variety of 
other alpha helices.
39,40
  The targets of these molecules can be easily tuned by changing 
the amino acid sequence to reflect that of a native ligand.  It is therefore postulated that 
HBSs can be designed to bind to each domain of p300.  These molecules can then be 
employed to study the effects each of these domains has on the maintenance of 
pluripotency and self-renewal in CICs. 
 
B.5. Scope of This Study 
 
The CIC model provides an intriguing hypothesis for cancer initiation, metastasis 
and development of chemotherapeutically resistant cancers.  While little is known 
directly about the biochemical pathways that control pluripotency and self-renewal in 
CICs, parallels between CICs and ESCs can be drawn.  The transcription factors Nanog, 
Sox2 and Oct4 have been established in ESCs as key proteins responsible for regulating 
self-renewal and pluripotency.  There is emerging evidence suggesting that the co-factors 
p300 and/or CBP may play a role transcription mediated by these factors.  By using 
exogenous ligands known to disrupt the binding capabilities of specific domains of p300 
and/or CBP as well as other biochemical techniques, the functions of these two proteins 
in CICs can be elucidated. 
This study in part aims to determine if CBP and p300 play a role in Nanog-driven 
gene expression.  Additionally, it is aimed at determining if small molecules that 
modulate CBP/p300 function are able to alter the ability of CICs to self-renew.  For 
initial experiments, we chose to examine the role of CBP and p300 in Nanog-driven 
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transcription as Nanog is known to be overexpressed in a variety of cancers, and 
knockdown of Nanog has been shown to cause a loss of self-renewal capabilities in 
CICs.
41,42 
 As no definitive evidence for involvement of CBP or p300 in Nanog-driven 
gene expression has been obtained, we first wanted to examine if these proteins were 
indeed involved in this process.  To accomplish this, RNAi that is specific for CBP or 
p300 was used in combination with a dual luciferase reporter assay to determine if either 
of these proteins has an effect on Nanog-driven gene expression.  Additionally, we 
wanted to determine which domain(s) of CBP and/or p300 were important in this process 
by using synthetic probes designed to target specific domains of CBP and p300.   
Finally, we wanted to determine if interfering with Nanog-driven gene expression 
would be sufficient to elicit a reduction in self-renewal.  As the expression of genes 
regulating self-renewal in ESCs is tightly controlled with several redundancies in place, it 
is possible that interfering with Nanog-driven transcription would be insufficient to block 
CICs’ ability to self-renew.  As such, the synthetic probes found to interfere with Nanog-
driven gene expression were dosed into CICs and the effects on cellular viability were 
observed as a measure of self-renewal capabilities.  
 
C. RNAi Studies of Dependence of CBP and p300 on Nanog-Driven Gene 
Expression 
 
 Nanog has been shown to contain two transactivation domains, the CD2 and WR 
domains (Figure III-6).
43
  In order to better understand the contributions each of these 
separate domains would have on recruitment of p300 and CBP, plasmids encoding a 
fusion protein consisting of the DBD of the yeast transcription factor Gal4 and the each 
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of the Nanog TADs were made by a rotation student in the Mapp laboratories, Victoria 
Assimon, for use in a luciferase reporter assay.  These fusion proteins were then used in 
combination with short hairpin RNAs (shRNAs) that had been shown to selectively target 
either CBP or p300 to determine their reliance on CBP and p300 in driving luciferase 
expression.
44
   
 
Figure III-6. Schematic of Nanog.  The transcriptional activation domains, WR and CD2 
are highlighted in blues. 
 
 
A significant decrease (p < 0.01) in Nanog CD2-driven luciferase activity was 
observed upon treatment with shRNA targeting p300 relative to treatment with a 
scramble shRNA.  However, a decrease in Nanog CD2-driven luciferase activity was not 
observed upon treatment with shRNA targeting CBP.  This indicates that Nanog CD2-
driven gene expression is reliant on p300 and not CBP in this system (Figure III-7).  The 
Nanog-WR domain did not activate to sufficient levels in our system to warrant further 
study (an average of 3-fold activation was observed). 
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Figure III-7. Nanog CD2-driven gene expression is dependant on p300 but not CBP.  a) 
Effects on Nanog CD2-driven luciferase expression by shRNA targeting p300 and CBP.  
Briefly, HEK 293T cells were plated in 24 well format (5x10
4
 cells/well) and allowed to 
adhere for 24 hours.  Cells were then transfected with a plasmid expressing Gal4 DBD-
Nanog CD2, a second plasmid bearing five Gal4-binding sites upstream of a firefly 
luciferase gene, a third plasmid expressing Renilla luciferase as a transfection control and 
a fourth plasmid expressing an shRNA scramble sequence, or shRNA targeting either 
CBP or p300 in a solution of Opti-Mem.  After 4 hours, the transfection solution was 
replaced with DMEM supplemented with 10% FBS and allowed to incubate for 48 hours 
before being read for luciferase activity using the Promega Dual Luciferase Assay 
according to manufacturer’s instructions.  Fold activities were then determined by 
dividing the firefly luciferase activity by that of the Renilla luciferase.  These values were 
then normalized so that the wells treated with scramble shRNA represent 100% activity.  
The values reported are the median of at least 7 trials with the indicated error 
representing the standard deviation.  b) Decrease in amount of CBP and p300 protein 
upon treatment with shRNA.  Treated cells were lysed for 20 minutes at 0 °C with 
Passive Lysis Buffer (Promega) and a protease inhibor cocktail (Invitrogen).  Lysates 
were centrifuged for 10 minutes at 14,000 rpm to remove membrande fragments.  
Supernatant was subjected to PAGE separation, followed by transference to PDVF 
membrane.  The membranes were then subjected to Western-blot analysis using (where 
appropriate) anti-CBP antibody (1:500), anti-p300 antibody (1:500) or anti-GAPDH 
antibody (1:1000) and a secondary antibody anti-mouse (1:500), anti-rabbit (1:500) or 
anti-mouse (1:1000) respectively.   
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 The results obtained from the reporter system provide insight into the reliance of 
p300 and CBP on transcription mediated by the Nanog CD2 domain.  It is possible, 
however, that p300 and CBP may not be required for Nanog-driven transcription in a 
native context.  It is therefore necessary to determine the effects of perturbing the 
function of p300 and CBP in a native context.  To this end, one of my co-workers in the 
Mapp laboratories, Conor Doss, transfected embryonal carcinoma cells with shRNA 
targeting p300 and used qPCR to measure the levels of mRNA of NANOG and OCT4 
upon knockdown of p300 (Figure III-8).  A significant decrease (p < 0.05) in NANOG  
mRNA levels was observed, indicating that p300 may play a role in the transcription of 
the NANOG gene.  As Nanog is known to auto-regulate, this may indicate that p300 is 
required for Nanog-driven gene expression.  More experiments are underway to 






























Figure III-8.   Effects on mRNA levels of NANOG and OCT4 upon knockdown of p300.  
Briefly, NCCIT cells (3.5 x 10
4
 cells/well) were plated and allowed to adhere for 12 
hours.   They were then transfected with pBABE.puro (encoding a puromycin-resistance 
gene) and either a shRNA plasmid targeting p300 or a scrambled shRNA control.  The 
cells were incubated for 24 hours after which time the transfection solution was removed 
and fresh RPMI + 10% FBS supplemented with 2.5 µg/mL puromycin (to select for 
transfected cells) was added.  After an additional 48 hours (72 hours post-transfection), 
the total RNA was harvested using the RNeasy Kit (Qiagen) and used as a template for 
the qPCR reactions.  The qPCR reactions were prepared following the Path-ID 2X qPCR 
Master Mix protocol (Applied Biosystems) with the appropriate probe (Applied 
Biosystems).  Each data point represents the mean of three trials with the error 




D. Effects of Synthetic Ligands of CBP/p300 on Nanog-Driven Transcription 
  
 The discovery that p300 is indeed necessary for Nanog-driven gene expression 
provided a gratifying initial result.  In order to better understand this interaction, however, 
it was necessary to determine which domain(s) of p300 are responsible for this 
interaction.  As the KIX and CH1 domains of p300 have been shown to be necessary for 
the maintenance of pluripotency and self-renewal of hematopoietic stem cells (HSCs), 
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these domains were first examined for their roles in Nanog-driven gene expression.
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The amphipathic isoxazolidine that binds the KIX domain of p300/CBP (444) was used 
as the probe to investigate the role of the KIX domain in Nanog-driven gene expression.  
The hydrogen bond surrogate designed to bind the CH1 domain of p300/CBP was used as 
a probe to investigate the role of the CH1 domain in Nanog-driven gene expression.  
 
D.1. Synthesis of Amphipathic Isoxazolidine 444 
 
Amphipathic isoxazolidine 444 was synthesized by a standard procedure (Scheme 
III-1).  Briefly, nitrile oxide III-2 undergoes a cycloaddition reaction with allyl alcohol 
to form isoxazoline III-3 in 90% yield.  This molecule can then undergo a Lewis Acid-
catalyzed Grignard addition to form isoxazolidine III-4 in good yield and moderate 
diastereoselectivity.  This molecule can then undergo a reduction reaction with 
benzaldehyde in the presence of sodium triacetoxy(borohydride) to yield III-5.  The 
benzylated isoxazolidine can then undergo a mesylation followed by azide 
displacement to yield the azido compound III-6 in 85% yield.  An oxidation of the 
olefin by reaction with osmium tetroxide allows for the formation of the dihydroxide 
III-7 which can then be cleaved and reduced to the final alcohol III-1.  The minor 
diastereomer is removed during the purification following the final reduction, resulting 




Scheme III-1. Synthetic route to formation of 444. 
 
 D.2. Results of Synthetic Probes on Nanog-Driven Luciferase Expression 
  
These studies were carried out by our collaborators, the Quintin Pan laboratories 
at Ohio State University, because of their expertise in viral transfections and dealing with 
head and neck squamous cell carcinomas (HNSCCs) a solid tumor model that contains 
both bulk tumor and CI cells.  For these studies, HNSCCs that were lentivirally 
transfected with plasmids encoding a Nanog-driven luciferase reporter were treated with 
30µM of 444.  A 22% decrease in luciferase activity was observed relative to DMSO 
control, indicating that Nanog-driven gene expression is effected by 444.  The HBS 
molecule targeting the CH1 domain (provided by the Arora laboratories at New York 
University) was tested in the same system (Figure III-9).  The HBS also elicited a dose-






Figure III-9.  Effect of synthetic ligands of p300/CBP on Nanog-driven gene expression.  
a) HNSCC cells treated with 444 exhibit a 22% decrease in luciferase levels relative to 
vehicle control, indicating a role of the KIX domain of p300 in Nanog-driven gene 
expression.  b) HNSCC cells treated with HBS exhibit a dose-dependent decrease in 
luciferase levels relative to vehicle control indicating a role of the CH1 domain of p300 
in Nanog-driven gene expression.  HNSCC cells that express a Nanog-driven luciferase 
gene were treated with the appropriate compound for 24 hours at which time the 
luciferase output was read using the Promega luciferase assay kit.  


































 These studies indicate that both the CH1 and KIX domains play a role in Nanog-
driven gene expression.  As other transcription factors have been shown to bind to 
multiple domains of p300, it is not surprising that multiple domains would be involved in 
Nanog-mediated transcription.
21,22
  These initial results were quite exciting as they 
proved that synthetic ligands of p300 had an effect on Nanog-driven gene expression.  In 
order to determine the effects that these molecules have on self-renewal, whole cell 
viability studies need to be conducted. 
 
E. Effects of Synthetic Ligands of p300 on Cellular Viability in a CIC Model System 
 
E.1. Initial Studies of Effectiveness of 444 in Altering Cellular Viability in a 
CIC Model System 
 
 
Initial studies were carried out in an embryonal carcinoma cell line (NCCIT) 
which has often been employed as a model stem cell system.  NCCIT cells were treated 
with increasing doses of amphipathic isoxazolidine for 24 hours before the relative 
viability of the cells were assayed using the WST-1 reagent.  It was found that treatment 
with 444 had a biphasic effect on the viability of the NCCIT cells.  No change in viability 
was observed relative to vehicle control when cells were treated with 0-60 µM of 444. A 
sharp decrease in the relative viability of the cells was observed between 60-100 µM.  
Cells treated with 100-140 µM of 444 showed a 50% decrease in viability relative to 
vehicle control.  When both 444 enantiomers were tested individually, similar results 




































Figure III-10. Effect of 444 on CIC model system.  NCCIT cells were plated in 96 well 
format (2.5x10
3
 cells/well) and allowed to adhere for 24 hours, after which time 
compound was added to the cells such that a final concentration of DMSO in all wells 
was 1% (v/v).  The cells were then incubated for an additional 24 hours at which time 
WST-1 reagent (Roche) was added to the cells.  The cells were incubated for another 4 
hours before the assay was read following manufacturer’s instructions.  The median value 
of 5 wells is reported for each treatment.  NCCIT cells display a biphasic response to 
treatment with 444 with lower doses of compound (10-60 µM) eliciting no significant 
difference in viability relative to vehicle control.  Doses above 100µM lead to 
approximately 50% decrease in cell viability.   Each of the two enantiomers were 
synthesized by a route similar to that of the racemic compound. 
 
NCCIT cells were also treated with a biphenyl-amphipathic isoxazolidine that has 
previously been shown to bind to Med23 (a component of the human mediator complex) 
a) 
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but not to the KIX domain CBP.
 46
  These cells did not exhibit a biphasic response; rather, 




Figure III-11. Effect of isoxazolidine that does not target CBP on CIC model system.   
The cells were treated as previously described for Figure III-10.  Cells exhibit a dose-
dependant decrease in viability when treated with III-8; a biphenyl-substituted 
isoxazolidine that has been shown to not bind CBP.  III-8 was synthesized by the same 
route as was described for III-7 with the exception that [1,1'-biphenyl]-4-carbaldehyde 
was used in the place of benzaldehyde during the fourth step of this reaction. 
 
 
An additional study was carried out to determine the effect of 444 on NCCIT cells 
over 72 hours.  Viability assays performed at 24, 48 and 72 hours post-treatment showed 




























inhibition over the course of the study relative to vehicle control.  Cells treated with 
greater than 90 µM 444, however, showed no growth over the course of 72 hours (Figure 
III-12).  These data indicates that 444 may be having a cytostatic effect rather than a 
cytotoxic effect on the cells.  This effect would be consistent with a decrease in the cells’ 
ability to self-renew.  As Nanog is known to control self-renewal, it was hypothesized 
that 444 may disrupt the function of Nanog, possibly by preventing p300 and/or CBP 
from acting as a co-factor in Nanog-driven transcription.  Accordingly, the effects of 444 
on Nanog-driven transcription were more directly tested. 
 
Figure III-12. Response of NCCIT cells to treatment with 444 over 72 hours.  Cells 
treated at concentrations of 444 from 10-60 µM exhibited no change in viability relative 
to vehicle control over the course of the 72 hour study.  Cells treated with 90-120 µM of 
compound exhibited no change in viability between hour 0 and hour 72.  This indicates 
that 444 may be having a cytostatic rather than cytotoxic effect on these cells.  For this 
study, cells were plated and dosed following the procedure outlined in Figure III-10.  The 
cells were then incubated for either 0, 24, 48 or 72 hours in the presence of 444 before 
being submitted to the WST-1 assay.   
 
As this sort of a biphasic response to 444 treatment has not been previously 
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CICs.  It was therefore decided that this hypothesis should be tested in a more 
complicated system. 
 
E.2. Effects of 444 in a Heterogeneous Tumor System 
 
HSNCC cell lines have been shown to contain cells that exhibit surface markers 
indicative of pluripotency.  As such, it was decided that the efficacy of 444 in targeting 
CICs over bulk tumor cells (cells that do not exhibit surface markers indicative of 
pluripotency) should be tested in the Pan laboratories to determine how CICs in a more 
complex, heterogeneous tumor model would respond to treatment with the small 
molecule.     
Head and neck cancer cell lines were treated for 24 hours with 444 (30 and 100 
µM) and cis-platinum (10 µM), the drug most commonly prescribed for treating head and 
neck tumors.  In order to determine the effects of treatment on the relative population of 
CIC versus bulk tumor cells, the relative population of cells expressing a pluripotency 
marker aldehyde dehydrogenase (ALDH) and the population of cells not expressing this 
marker were determined by FACS before and after treatment.  It was discovered that cis-
platinum treatment in two cell lines, SCC15 and SCC25, resulted in a 5 and 3 fold 
enrichment of CICs, indicating that these cells are resistant to cis-platinum treatment 




Figure III-13.  ALDH+ CICs from head and neck cancer cell lines are resistant to cis-
platium treatment but not treatment with 444.  a) Head and neck cancer cell lines SCC15 
and SCC25 were treated with DMSO or cis-platin (10 µM) for 24 hours.  Cells were 
analyzed for ALDH expression by FACS using the ALDEFLUOR assay.  A 5 and 3 fold 
enrinchment in CIC populations were observed for the cells treated with cis-platinum in 
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both cell lines.  b) Head and neck cancer cell line SCC47 was treated with DMSO or 444 
(30 µM) for 24 hours.  Cells were analyzed for ALDH expression by FACS using the 
ALDEFLUOR assay. An 18% decrease in the CIC population was observed for cells 
treated with 444 versus vehicle control. 
 
 
Conversely, cells treated with 444 exhibited a decrease in ALDH+ cells (18% 
when treated with 30 µM 444 and 70% when treated with 100 µM 444) but the 
population of ALDH- cells remained unchanged (Figure III-13b).  This finding confirms 
that pluripotent cellular viability is more affected than differentiated cellular viability by 
treatment with 444.   
To date, there have been very few examples of small molecules capable of 
targeting CICs, with no current strategies in place to directly target the functioning of 
Nanog.
4,9,47 
 A small molecule such as 444 that targets CICs preferentially over bulk 
tumor cells could be of great value in understanding the cellular processes that must be 
perturbed in order to decrease the population of CICs.  If these processes are unique to 
CICs, it is possible that a therapeutic could be generated that would just target these cells, 
while leaving differentiated adult cells and normal stem cells in tact.  Such an 
advancement would provide enormously useful in the field of cancer therapeutics. 
 
F. Conclusions and Future Directions 
 
 The cancer initiating cell hypothesis provides a novel perspective on the cause 
and potential treatment for chemotherapeutic-resistant cancers.  Several solid tumors 
have been found to contain cells that exhibit pluripotency markers and overexpress 
transcription factors and other proteins commonly associated with stem cells.  As the 
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transcription factors Nanog, Oct4 and Sox2 have been found at elevated levels in several 
types of solid tumors, targeting the functions of these proteins may lead to therapeutic 
agents capable of inhibiting pluripotency and self-renewal in CICs.   
 Evidence from embryonic stem cell studies indicate that the co-activator p300 
plays a role in transcription mediated by these factors; however no direct evidence of 
these types of interactions has been obtained in CICs.  Work performed in the Mapp 
laboratories indicates that Nanog-driven gene expression is dependent on p300 but not 
CBP in a luciferase reporter context.  Additionally, knockdown of p300 causes a decrease 
in levels of NANOG mRNA levels.  Studies performed with synthetic ligands of p300 
indicate that both the KIX and CH1 domains of p300 are involved in Nanog-driven gene 
expression with a significant (p < 0.01) decrease in Nanog-driven luciferase expression 
upon treatment with 30µM 444.   
 Studies performed in NCCIT cells indicate that 444, a small molecule capable of 
targeting the KIX domain of CBP causes a decrease in viability at concentrations greater 
than 60 µM.  A time course study indicates that 444 has a cytostatic effect on NCCIT 
cells.  Follow up studies were performed in a heterogeneous tumor system that consists of 
both bulk tumor cells and CICs.  These studies indicate that treatment with 444 results in 
an 18% reduction of CICs over the course of 24 hours, with no observed effects on the 
bulk tumor cell population.  Similar studies testing the effects of the HBS on cellular 
viability are underway.   
 These findings taken together offer a new insight into the mechanism of Nanog-
driven gene expression.  This is the first time that a direct correlation between p300 and 
Nanog-driven gene expression has been established.  This is also the first time that a 
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synthetic molecule has been shown to affect Nanog-driven gene expression.  This finding, 
coupled with the finding that 444 is able to reduce CIC viability in two cellular contexts 
provides evidence that inhibiting the function of transcription factors such as Nanog may 
prove to be a valuable strategy for formation of CIC-specific therapeutic agents.  These 
studies, however, have also raised a number of questions about the nature and 
mechanisms by which p300 is involved in Nanog-driven gene expression and the 
maintenance of self-renewal and pluripotency. 
 First, it is unclear if the KIX and CH1 domains of p300 are the only domains 
responsible for mediating Nanog-driven gene expression.  More experiments must be 
carried out to determine if the remaining domains of p300 are required for Nanog-driven 
gene expression.  To this end the individual domains of p300 are being overexpressed in 
cells expressing the Nanog-driven luciferase reporter and in NCCIT cells.  The critical 
domains should cause a change in luciferase levels whereas those that are not involved in 
this process should cause no change.   
 Additionally, the full effects of 444 and the HBS on self-renewal and pluripotency 
have yet to be characterized.  While the initial studies show a decrease in CIC population, 
indicative of a loss of self-renewal ability, their effects on pluripotency have yet to be 
determined.  Work in the Mapp and Pan laboratories is currently underway aimed at 
discovering if these small molecules cause CICs to differentiate.  Cells treated with 444 
and the HBS are being examined for the expression of key germ-line differentiation 
markers.   
 Additionally, it should be determined if 444 has in vivo efficacy, and if it affects 
CICs preferentially to other stem cells in the body such as hematopoietic stem cells.  In 
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order to determine this effect, in vivo studies of the effects of 444 on mice are planned.  
For these studies, HNSCC cells with constitutive luciferase expression will be implanted 
into NOD/SCID mice.  After initial tumors have formed, the mice will be treated 
intravenously with 444 and the growth of the initial tumor and the extent of lung 
metastasis will be monitored for 4-6 weeks.  At the termination of the experiment, the 
remaining tumor bulk will be analyzed for its CIC content.  Additionally, the effects on 
normal stem cells will be monitored to determine if 444 preferentially targets CICs.  It is 
likely that some of the probes used in cellulo will have to be modified to achieve 
optimum in vivo efficiency.   
 Also, to expand this study, the dependence on p300 and CBP of Oct4 should be 
examined.  Initial luciferase reporter studies using Gal4-fusion proteins in conjunction 
with shRNA indicate that neither of the two activation domains of Oct4 are dependant on 
either p300 or CBP for transcription (Figure III-14).  Conversely, it has been previously 
reported that in similar reporter contexts, Sox2-mediated transcription is dependent on 
p300.  However, it is unknown if either of these activators rely on p300 or CBP in their 
native promoter contexts in CICs.  In order to establish this, experiments similar to those 
conducted by the Pan laboratories in which the native Nanog promoter was appended 





































Figure III-14.  Dependence on p300 and CBP for Oct4-mediated transcription. a) A 
scheme of Oct4 is shown with the two activation domains highlighted in blue. b)  
Plasmids were made encoding fusion proteins of the Gal4 DBD with each of the Oct4 
TADs and used in a luciferase reporter assay as previously described.  Neither activation 
domain of Oct4 was dependent on either CBP or p300 for activation. 
 
 
 Finally, the effects of knocking down p300 and CBP on pluripotency and self-
renewal in CICs should be monitored.  First, these studies will help to further define the 
disparate roles that p300 and CBP play in differentiation.  Secondly, they will provide a 
measure for how extensively these proteins are involved in the maintenance of 
pluripotency and self-renewal in a CIC population.  CICs have many mechanisms in 
place for avoiding differentiation.  If elimination of p300 and/or CBP is sufficient to 
induce differentiation, these proteins may prove to have vital therapeutic relevance in the 






HBS was provided by the Arora laboratories at New York University.  Synthesis 
of molecule III-7, the individual enantiomers of the compound and of molecule III-8 
were performed according to standard procedures.
33,46,48  
These compounds were purified 
prior to cell studies by passage through a disposable C8 column in 10% ammonium 
acetate in methanol after which they were lyophilized until dry.  Oct4 and Nanog full 
length plasmids were purchased from Addgene.  CBP and p300 shRNA plasmids were 




Assay for Dependence of Nanog-driven Transcription on p300 and CBP. 
 HEK293T cells were purchased from the American Type Culture Collection 
(ATCC) and plated onto treated polystyrene Petri dishes (Corning) with 15 mL of 
DMEM (+ 4.5 g/L d-glucose, + l-glutamine, -sodium pyruvate, + 10% FBS) (Invitrogen).  
The cells were grown at 37 °C and 5% CO2 to 80-90% confluence.  Upon reaching the 
desired confluence, the DMEM was removed and 5 mL 0.25% trypsin was added.  The 
cells were incubated with the trypsin solution for 5 minutes at 37 °C and 5% CO2.  
Following the incubation, 5 mL of DMEM were added and the resultant solution was 
gently pipetted several times to ensure removal of all cells from the dish surface.  The 
solution was centrifuged in a 15 mL Falcon tube at 1000 rpm for 4 minutes in a Fisher 
Centrific centrifuge.  The supernatant was removed and the cell pellet was resuspended in 
10 mL of DMEM.  The concentration of cells was calculated using a Hausser Scientific 
improved Neubauer phase counting chamber hemocytometer.  Based on the determined 
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concentration, the cells were diluted to 5 x 10
4
 cells/mL in DMEM.  1 mL of the cell 
solution was then added to each well of a Microtest flat-bottom, low-evaporation-lid 24-
well plates (Beckton-Dickinson) and the plated cells were incubated for 24 hours at 37 °C 
and 5% CO2.  The media was removed from the plated cells and they were treated with 
Opti-Mem (+ HEPES, 2.4 g/L sodium bicarbonate, + l-glutamine) (Invitrogen) and then 
transfected. 
 The transfection procedure consisted of first mixing appropriate plasmids and 
Lipofectamine 2000 together in Opti-MEM media for each well being transfected.  After 
a 20 minute incubation at room temperature 500 µL of the solution was placed in the 
appropriate wells and the cells were incubated for 4 hours at 37 °C and 5% CO2.  At the 
end of the 4 hours, the transfection solution was removed and 1 mL of fresh DMEM was 
added to each well.  The cells were then incubated for 48 hours at 37 °C and 5% CO2. 
 Following the 48 hour incubation, the media was removed from each well and the 
cells were washed once with PBS buffer.  100 µL of passive lysis buffer (Promega) was 
added to each well and the cells were incubated for 20 minutes at room temperature on an 
orbital shaker.  Subsequently, the lysate was mixed by pipetting and 25 µL of lysate was 
added to a cuvette along with 20 µL Luciferase Assay Reagent II (Promega) and the 
luminescence was recorded.  Then 25 µL Stop & Glo reagent (Promega) was added and 





 HEK293T cells were grown as previously described.  For plating, 2 x 10
5
 cells 
were plated per well in Microtest flat-bottom, low-evaporation-lid 6-well plates 
(Beckton-Dickinson) and the plated cells were incubated for 24 hours at 37 °C and 5% 
CO2. The media was removed from the plated cells and they were transfected with Opti-
Mem (+ HEPES, 2.4 g/L sodium bicarbonate, + l-glutamine) (Invitrogen) and then 
transfected. 
 The transfection procedure was the same as previously reported with the 
exception that 2.5 mL of the transfection solution was placed in the appropriate well.  At 
the end of the 4 hours, the transfection solution was removed and 1 mL of fresh DMEM 
was added to each well.  The cells were then incubated for 48 hours at 37 °C and 5% CO2.   
 Following the 48 hour incubation, the DMEM was removed.  The cells were then 
incubated with 100 µL 0.25% trypsin for 5 minutes at 37 °C and 5% CO2.  After this time, 
500 µL DMEM was added to each well and the resultant solution was gently pipetted 
several times to ensure removal of all cells from the dish surface.  The solution was then 
transferred to 1.5 mL Eppendorf tubes where the solution was again gently pipetted to 
ensure homogenization.  The concentration of cells harvested from each well was 
calculated using a Hausser Scientific improved Neubauer phase counting chamber 
hemocytometer for normalization purposes.  The cells were then centrifuged at 14,000 
rpm for 1 minute and the supernatant was discarded.  The cell pellet was then washed 2x 
in cold PBS buffer.  The cells were then lysed with passive lysis buffer (Promega) with a 
proEt3Nse inhibitor cocktail (Invitrogen) (volume determined such that there were 2,000 
cells/ µL of lysis solution in the final mixture) on ice on an orbital shaker for 20 minutes. 
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 The lysate was cleared by centrifugation at 14,000 rpm for 10 minutes then mixed 
with loading dye and DTT (final concentration of 1%) and heated at 95 °C for 9 minutes.  
20 µL of sample was loaded per well on a 4-12% tris/glycine gel in MOPS buffer (CBP) 
or a 3-8% tris/acetate gel in tris/acetate buffer (p300) and separated by PAGE for 120 
minutes (150V, 200mA).  Proteins were transferred to a PVDF membrane for 120 
minutes (45V, 200mA).   
 The membranes were then blocked (10mM PBS, pH 7.4, 1% (v/v) Tween-20, 2% 
(v/v) non-fat milk) for 1 hour at rt.  After 1 hour, the appropriate primary anti-body was 
added and the membrane was incubated overnight at 4 °C on a shaker.  For CBP 
detection: mouse monoclonal anti-CBP antibody (1:500, Santa Cruz Biotechnology), for 
p300 detection: rabbit polyclonal anti-p300 antibody (1:500, Santa Cruz Biotechnology), 
for GAPDH detection: mouse monoclonal anti-GAPDH antibody (1:1,000, Santa Cruz 
Biotechnology).  After incubation with primary antibody, the membrane was washed (3x 
10 mins) (10mM PBS, pH 7.4, 1% (v/v) Tween-20) on an orbital shaker at rt.  The 
membranes were then incubated with an appropriate horseradish peroxidase labeled 
secondary antibody in a buffer (10mM PBS, pH 7.4, 1% (v/v) Tween-20, 2% (v/v) non-
fat milk) for 1 hour at rt.  (For CBP anti-mouse antibody (1:500, Santa Cruz 
Biotechnology), for p300 anti-rabbit antibody (1:500, Santa Cruz Biotechnology), for 
GAPDH anti-mouse antibody (1:1000, Santa Cruz Biotechnology).  After 1 hour, the 
membrane was washed (3x 10 mins) (10mM PBS, pH 7.4, 1% (v/v) Tween-20) on an 
orbital shaker at rt.  Bands were visualized using the ECL plus Western Blot Detection 
System (GE Healthcare). 
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Cellular Viability Assays. 
 NCCIT cells were purchased from the American Type Culture Collection (ATCC) 
and plated onto treated polystyrene Petri dishes (Corning) with 10 mL of RPMI + 10% 
FBS (Invitrogen).  The cells were grown at 37 °C and 5% CO2 to 80-90% confluence.  
Upon reaching the desired confluence, the RPMI was removed and 5 mL 0.25% trypsin 
was added.  The cells were incubated with the trypsin solution for 5 minutes at 37 °C and 
5% CO2.  Following the incubation, 5 mL of RPMI were added and the resultant solution 
was gently pipetted several times to ensure removal of all cells from the dish surface.  
The solution was centrifuged in a 15 mL Falcon tube at 1000 rpm for 4 minutes in a 
Fisher Centrific centrifuge.  The supernatant was removed and the cell pellet was 
resuspended in 10 mL of RPMI.  The concentration of cells was calculated using a 
Hausser Scientific improved Neubauer phase counting chamber hemocytometer.  Based 
on the determined concentration, the cells were diluted to 2.5 x 10
4
 cells/mL in DMEM.  
100 µL of the cell solution was then added to each well of a Microtest flat-bottom, low-
evaporation-lid 96-well plates (Beckton-Dickinson) and the plated cells were incubated 
for 24 hours at 37 °C and 5% CO2.  After 24 hours, compound was added as a solution of 
DMSO (1% final concentration of DMSO) and incubated for 24-72 hours at 37 °C 5% 
CO2.  After 24, 48 or 72 hours of incubation, cells were treated with WST-1 (Roche) 
according to manufacturer’s instructions.  The plates were read on a Tecan Genios Pro 
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Design and Implementation of a Peer-Led Module for Teaching Practical Research 







 The need for formal ethics training outside of the student-advisor relationship has 
been well established.  As part of my thesis work, a collaborator (Christopher Taylor) and 
I have designed and implemented a peer-led module for teaching practical research ethics.  
We postulated that senior graduate students would be effective as teachers of research 
ethics as they would bring a unique view of problems facing incoming graduate students.  
We also hypothesized that incoming graduate students would be more open and honest 
when discussing ethical issues when they were with a group of peers.  In teaching this 
module, we developed a series of data interpretation exercises and case studies for the 
students to work through based on dilemmas that we, the peer leaders, or members of our 
cohorts had faced during our first two years of graduate school.  In order to assess the 
effectiveness of this module, we examined student feedback, responses students gave 
during large group discussions of case studies, and the reactions of the chemical 
community as a whole.  The students’ responses during the large group discussions 
incorporated many of the ideas that were presented earlier in the module, indicating that 
                                                 
a Portions of the chapter are reported in Danowitz, A.M. and Taylor, C.E. “Integrating a Peer-Taught 
Module on Practical Research Ethics into the Graduate Student Orientation Curriculum.” Accepted 
Manuscript J. Chem. Educ. 
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the module was successful as the students were beginning to understand the complexities 
involved in addressing ethical concerns.  Additionally, the positive responses from the 
student evaluations and the positive feedback from the chemical community indicate that 
this is a useful module. 
 
B. Introduction 
 B.1. Examples of Scientific Misconduct  
 
The need for explicit, formal instruction in research ethics and professionalism 
has been well established. 1,2  This need has been highlighted in recent years by several 
major scientific scandals.  Cases such as that of Jan Hendrick Schön, the former Bell 
Laboratories researcher who was found guilty of 16 counts of scientific misconduct in his 
research relating to nanomaterials, Wu Suk Hwang, the Korean researcher who falsified 
data regarding the creation of human stem cells, and Marc Hauser, the cognitive scientist 
who was recently found guilty by Harvard University of engaging in scientific 
misconduct have garnered international attention.3,4,5  While these egregious cases of 
scientific misconduct are the exceptions rather than the rule, other, less widely publicized 
forms of misconduct are much more common. 
In a study conducted at Arizona State University, 84-91% of undergraduate 
students in seven biology and zoology courses admitted to“almost always” or “often” 
manipulating laboratory data to obtain a desired result. 6  In a study completed in 2005 of 
3,247 faculty members and postdocs who received NIH funding (either an R01 grant for 
faculty or an F32 or T32 grant for postdocs), 33% of respondents admitted to 
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participating in at least one of ten behaviors that were determined by the designers of the 
survey to be the most  serious questionable research practices.  These questionable 
practices include among others: falsifying or “cooking” research data, overlooking 
others’ use of flawed data or questionable interpretation of data, and changing the design, 
methodology or results of a study in response to pressure from a funding source.7  A 
particularly poignant example of scientific misconduct for the University of Michigan is 
the case of a postdoc, Vipul Bhrigu,  in the Comprehensive Cancer Center who was 
arrested for, and pleaded guilty to, charges of malicious destruction of personal property 
after spending several months sabotaging his colleague’s experiments.8  These reports of 
moral transgressions highlight the prevalence of misconduct in the modern academe, and 
underline the need for increased awareness of ethical issues and decision making among 
scientists at all levels.    
 
B.2. Defining Scientific Misconduct 
 
One of the traditional problems facing scientists dealing with ethical dilemmas is 
that scientific misconduct has been notoriously difficult to define.9  In 2004, the Office of 
Research Integrity (ORI) — a division of the Department of Health and Human Services 
that overseas and directs Public Health Service research integrity — introduced a series 
of guidelines for the Responsible Conduct of Research (RCR) in an attempt to define the 
legal threshold for defining cases of research misconduct.  Under this system, research 
misconduct is defined as: 
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Fabrication, falsification, or plagiarism in proposing, performing, or reviewing 
research, or in reporting research results.  (a) Fabrication is making up data or 
results and recording or reporting them. (b) Falsification is manipulating 
research materials, equipment, or processes, or changing or omitting data 
or results such that the research is not accurately represented in the research 
 record.  (c) Plagiarism is the appropriation of another person’s ideas, processes, 
results, or words without giving appropriate credit.  (d) Research misconduct does 
not include honest error or differences of opinion.10 
 
While this definition provides a useful standard for gauging research misconduct, several 
types of questionable research practices fall outside of this definition but still pose a 
threat to the scientific enterprise.7  For example, the sabotage committed by Bhrigu 
resulted in an estimated loss of $72,000 in resources and person-hours but does not fall 
under the RCR definition of misconduct.8   Situations like this where ethically dubious 
acts were clearly committed, highlight the downfall of a narrow definition of scientific 
misconduct.  An effort to incorporate both the RCR guidelines and a broader definition of 
questionable research practices should be made in designing research ethics courses. 
 
 B.3. Addressing Issues of Scientific Misconduct and Research Ethics 
 
 Just as scientific misconduct has been traditionally difficult to define, it has been 
similarly difficult to effectively formally address.  Part of this issue stems from 
identifying the root causes of scientific misconduct.  One hypothesis is that scientific 
misconduct is the action of individual “scoundrels among scientists” who commit 
ethically dubious acts to further their own goals.11  It would be naïve to assume that any 
amount of formal ethics training would prevent all individuals who have decided on an 
ethically dubious course of action from doing so.  However, formal ethics training would 
 114 
provide scientists the tools they need to effectively address problems that arise from their 
less ethically-minded colleagues before they become large, public scandals.11,12  This is 
highlighted by the case of sabotage that occurred at the University of Michigan last year.  
While the victim of the sabotage first noted suspicious things occurring with her research 
in December 2009, a formal investigation into the issue was not launched until six 
months later, when the victim was first accused of sabotaging her own work.8  Had a 
research environment existed where ethical considerations were prominently discussed, it 
is possible that the nature of the sabotage could have been uncovered and dealt with 
much sooner, and with less cost in time and money. 
 Another school of thought cites the competitive nature of modern science as 
fostering an environment in which otherwise ethically minded researchers commit 
ethically dubious acts in response to external pressures.11  While it stands to reason that 
formal ethics education could help to bring about changes in both the environment in 
which scientists works and the way that scientists respond to these pressures, there is 
limited evidence that this is the case.11  It has been noted, however, that formal education 
programs have the best chance of succeeding if they are “creative,” emphasize 
practicality in addressing concerns and provide researchers with a support network whom 
they can contact when issues regarding research ethics arise.12 
 Multiple strategies have been developed for creatively incorporating research 
ethics into the standard graduate and undergraduate curriculums including: introduction 
of ethical principles as part of a peer led structured study group,13 implementing courses 
focused specifically on research ethics,14,15 integrating ethical discussions into traditional 
chemistry courses,16 and the design of a flexible model that can be applied to a variety of 
 115 
scientists in many different contexts.17 As researchers who are responsible for generating 
and publishing original research, and as individuals who are often carrying out research 
full-time for the first time in their lives, graduate students are a critical audience for these 
discussions. 
After attending the Teaching Research Ethics conference at the Poynter Center at 
Indiana University,18 and in consultation with members of the University of Michigan 
chemistry faculty, we developed a peer-led ethics module to be presented to the entire 
cohort of incoming chemistry graduate students during graduate orientation. We 
proposed that a peer-led program would send a positive message about the students’ 
responsibility in taking ownership of their education.  Additionally, it would draw the 
students’ attention to these issues in their first few weeks of graduate school. We taught 
this module for the first time in 2009 and then again in 2010. 
 
C. Rationale for Utilizing Peer-Leaders 
 
 The most striking aspect of this approach to teaching research ethics is the use of 
peer leaders in teaching this module.  It was believed that having senior graduate students 
as instructors would be advantageous for several reasons.  First, it was proposed that a 
peer-led program would send a positive message to the incoming students about the roles 
that ethics plays in every day research.  It was felt that the incoming students would note 
that ethics is important to their peer group and should therefore, by extension, be 
important to them.  As it has been suggested that a research ethics course is most 
effective when it influences individuals instead of “merely satisfies an item on a ‘check-
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off’ list for [an] institution,” the peer-led method should prove to be particularly effective 
at changing individual view points and behaviors.12      
Second, we wanted to take advantage of the knowledge that senior graduate 
students have of the research environment in their own department.  Senior students have 
a wealth of very recent experiences to draw from when discussing ethical issues with 
younger students.  They are well aware of the current difficulties facing students in an 
ever-changing research environment.  This knowledge is especially valuable in writing 
case studies.  We drew on dilemmas faced by ourselves and our peer group when 
designing the case studies.  This ensured that the case studies presented would be relevant 
to the experiences of first and second year graduate students.  
Finally, it was believed that students would be more honest when discussing their 
views of ethically dubious situations if they were in a group of their peers.  There is a real 
possibility that first year students might censor their responses in order to impress a 
faculty member. 
It must be noted, however, that senior graduate students lack a firsthand faculty 
perspective on these issues. For this reason, it is extremely useful to consult with faculty 
members in determining discussion points and potential solutions for each case study.  
An open and honest dialogue between the peer leaders and members of the faculty is 
considered to be key in the success of this module.  
 
D. Module Goals and Design 
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In line with the idea that the drive for personal success and desire to comply with 
external pressures can outweigh moral concerns, the module was designed around the 
idea that most students do not start out with the intention of committing morally dubious 
acts.11,13,15  Rather, they might do so in response to the pressures that they face as 
graduate students (Figure IV-1).  This line of reasoning indicates that ethical decision-
making and the ability to navigate the conflicts and hazards of graduate school are closely 
intertwined.15  The main vehicle employed for facilitating discussions was case studies 
designed by the peer leaders. 
 
Figure IV-1. Flow chart detailing how students who are faced with a dilemma can, 
through their own poor decision making, become set on a path leading them to commit 
gross misconduct. 
 
The first goal in designing this module was to provide students with examples of 
potential moral dilemmas that they could relate to.  As noted by Kovac, "It is essential 
that students be able to relate to both the context and the characters [of a given situation].  
If the people and the scenario are too distant, students will tend to see the situation in 
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simplistic right-or-wrong terms." 19  In keeping with this idea, the case studies were based 
on situations that members of the 2006 and 2007 chemistry cohorts had faced during their 
first two years of graduate school.   
In addition to designing the case studies so that students could relate to them, an 
emphasis was placed on practical ethical reasoning skills.  To begin with, students were 
encouraged to identify when a situation involved ethical considerations and when it did 
not.  In particular, students were instructed to distinguish between facts and rumor or 
gossip when examining possible misconduct on the part of a co-worker.  Students were 
also asked to propose several solutions to each of the problems presented.  In particular, 
students were asked to devise solutions that would allow them to succeed in meeting 
external requirements without committing misconduct. 
In order to give students the tools they need for solving moral dilemmas, the final 
objective was to present students with an over-view of the departmental and campus-wide 
resources for conflict resolution.  As students are often unaware of resources other than 
their advisors and more experienced lab-mates, their attention was drawn specificially to 
bodies such as the Graduate Committee and the Ombud’s office that can help them with 
problem solving.  Specifically, students were encouraged to begin to differentiate which 
types of problems would be appropriate to bring to each resource. 
In order to meet these goals, we developed six case studies and a data 
interpretation exercise (see Section K) that were used as vehicles to discuss issues such as 
authorship, plagiarism, resolution of intra-lab conflict, and data integrity from the 
perspective of a first or second year graduate student.  
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E. Module Layout and Content 
 
We implemented this module in two, two-hour blocks over the course of two days.   
The sequence began with a brief presentation on the resources that are available to 
graduate students in dealing with conflicts.  These discussions were centered on those 
conflicts that could either lead to misconduct on the students’ part or stem from the 
misconduct of other researchers. Students participated in a brainstorming session that 
addressed different sorts of conflicts that can arise in graduate school. The peer leaders 
then guided a large group discussion about the most appropriate venues for resolving 
these problems.   This discussion included potential steps for escalation of unresolved 
problems, and of alternative courses of action for cases where the usual resource—such 
as the student's advisor—were not appropriate.  
Prior to the discussion of the case studies and data interpretation exercise, the 
students were given a hand-out titled “A Format for Ethical Decision Making” (Box IV-
1).  The peer leaders then discussed the issues presented in this framework.  Specifically, 
the students’ attention was drawn to the need for postulating several solutions to a given 
situation.  Also, the various ‘tests’ listed in the handout were discussed as a moral 
barometer for judging these solutions.  It was hoped that students would incorporate these 
ideas when thinking about and discussing moral dilemmas in the future as evidence that 
they were becoming proficient in identifying and addressing such problems.  
Most of the module was based on case studies that focused on dilemmas that 
students might face as first or second year graduate students.  Students discussed cases in 
small groups (four to six students) with the discussion leaders moving from group to 
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group in order to facilitate discussion.  To ensure that each group contained the expertise 
necessary to address the data presented in the data interpretation exercise, the students 
were divided such that each group contained at least one student specializing in each of 
the different chemistry subdivisions.  The entire group then discussed the case, with 
students volunteering solutions or feedback on other students' solutions.  At this stage, the 
discussion leaders acted as moderators and guided the group towards a general consensus 
on the best courses of action for each situation.  In both the small and large group 
discussions, students were encouraged to consider the long term consequences of each 
proposed action and to think about other stakeholders who may be affected by their 
actions. Peer leaders and students also discussed the differences between professional and 




















Box IV-1. A Format for Ethical Decision Making.    
A Format for Ethical Decision Making 
Adapted from a handout written by Professor Michael Davis, for the Teaching 
Research Ethics conference in 2009. Used with permission.  
 
1) Determine the problem.  
The initial problem may be an explicitly ethical one (e.g. 'I think this data was 
fabricated') or it may not be (e.g. 'I am going to miss a research deadline').  
 
2) Determine/check facts. 
As much as possible, try to separate objectively verifiable facts from suspicions 
or rumors. In many cases, the issue may change or disappear upon careful 
consideration.  
 
3) Consider limitations and objectives.  
There will probably be many goals involved in a situation – maintaining 
personal integrity, advancing your career, making a favorable impression with 
your advisor or other faculty members, your relationship with your peers, etc.  
 
4) Develop a list of 2-3 options.  
Be specific about courses of action – who would you talk to, how would you 
discuss the issues, etc. 
 
5) Test Options.  
The following are good examples of tests that are not necessarily dependent on 
specific ethical theories.  
 
Harm test – Does this option do less harm than any of the other alternatives? 
 
Publicity test – Would I want my choice of this option known throughout the 
department? 
 
Defensibility test – Could I defend this choice in front of faculty members or 
other authorities? If so, what would I say?  
 
Reversibility test – Would I still think this was the best option if I were one of 
the people adversely affected by it. 
 
6) Choose an option based on steps 1-5.  
 
7) Consider what you can do to make it less likely that this issue will come 
up again. 
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  In addition to case studies, we used an exercise and group discussion that dealt 
with interpreting and presenting ambiguous data to illustrate the ethical dimensions of 
this process. After a brief presentation on what qualifies as fabrication, falsification and 
plagiarism, students were presented with examples of data such as synthetic yields 
obtained when testing the efficacy of two different ligands (see Section K for examples).  
The students were also given a list of potential conclusions that could be drawn from the 
data.  They then discussed circumstances under which a given conclusion would or would 
not be valid. In the latter case, students also considered whether inappropriate 
conclusions represented poor science or misconduct and discussed the factors that 
determine this distinction.  Additionally, students discussed the differences between a 
reasonable disagreement between scientists and misconduct.  The module ended with two 
'off the record' question and answer sessions, in which students could ask the discussion 
leaders questions about graduate school, or broach any unaddressed concerns that they 
had.  In the first session, only the peer leaders were present.  For the second session, a 
faculty member was present so that students could get the faculty’s view of any questions 
they had. 
 
F. Student Discussions of Case Studies 
 
The nature of the responses given by the new graduate students was used as one 
means to assess the effectiveness of the module. If these discussions were successful, 
students should assimilate the lessons and identify the larger moral dimensions of the 
situations presented in the case studies.  They should also propose solutions that allow 
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them to maintain both their ethical and professional integrity, while still meeting the 
demands of graduate school.  
In the case study titled “Key Result” (Box IV-2), students were presented with a 
situation set during their preparation for candidacy.  Many of the student responses 
referred to ideas from the ‘Format for Ethical Decision Making’ handout that had 
previously been discussed with them.  Several students brought up the potential affects of 
their actions on their advisor or collaborators who are additional stakeholders in the 
situation. Other responses included assessment of potential long-term effects—for 
example, that feigning ignorance of the needed control in situation A could set the 
student up for further acts of fabrication or falsification if they are faced with the 
invalidation of their ‘results’ later on.  
In addition to recognizing the ethical issues embedded in the case study, students 
proposed solutions that allowed them to meet the demands of graduate school without 
committing misconduct or setting themselves up to do so in the future. For example, in 
situation B, the possibility was raised that students may be able to postpone candidacy 
until the systematic error has been fixed, rather than present suspect data. For situation A, 
students discussed ways to present the limitations of the data (i.e. “absent this control we 
see…”) that might allow them to discuss their data without misrepresenting their results.  
These responses indicate that students are seeing beyond the simplistic binary dilemma of 
committing a morally dubious act or failing to meet imposed standards. 
For another case study (Box IV-3), students discussed the possibility of 
misconduct on the part of a coworker.  These sorts of problems may arise when multiple 
scientists contribute to a project. It is therefore important for students to think about how 
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to determine if misconduct has occurred.  Students should also practice professional and 
courteous ways of broaching these types of concerns with other scientists.  
For this exercise, students proposed specific details that would lead them to 
believe that either (a) misconduct had been committed by the previous student or (b) the 
previous student had not committed misconduct.  This gave students the opportunity to 
become creatively engaged with the material, and opened up the discussion to a wider 
variety of circumstances and issues than if they were given a single, completely defined 
case study. In one instance, a student proposed a situation based directly on his previous 
research experience. This illustrated both the plausibility of these sorts of situations and 
the importance of the resulting discussion.  
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Box IV-2. Example of a case study presented to students.  In this situation, students were 









Case Study - “Key Result” 
 
You are a second year student, and you have been working in your thesis 
lab for several months. You are working on the document that you will submit to 
your candidacy committee. Your thesis research is quite ambitious and your 
advisor has warned you that your committee members are likely to be skeptical. 
Nevertheless, you are confidant that it will work and by hard work and luck, have 
acquired an early result from one of your key experiments that demonstrates proof 
of concept for your work. While you are writing the paper, a fact comes to light 
that casts doubt on the veracity of your results (see below). There is not time to 
repeat the experiment before the deadline for your candidacy document.  
In which of these situations (and with what qualifiers) is it permissible to 
include the questionable experimental results in your document and presentation?  
 
Situation A)  
You realize that you did not perform a necessary control to rule out a likely 
confounding factor in your key experiment.     
 
Situation B)  
A serious technical problem is brought to your attention (e.g. the instrument you 
collected data on was incorrectly calibrated, etc).    
 
Situation C)  
You find a paper with an experiment very similar to yours, but which has a 
significantly different result, and from which the authors draw conclusions which 





Box IV-3. Example of a case study presented to students.  In this situation, students were 
given an example of a situation where they suspect misconduct has been committed by a 
co-worker. 
 
The second portion of this case study centered on appropriate responses to 
situations where a student believed misconduct may have occurred. Specifically, students 
proposed professional ways of dealing with this conflict and noted the importance of 
presenting the facts of the case, rather than their suspicions or opinions about the former 
student. During these discussions, students again brought up the possible affects on 
Case Study - “Continuing a Project” 
 
You have inherited a project from a 6th year graduate student who has left 
the lab.  The student's work was published as a communication, and your thesis 
research will be a series of follow-up studies based on her initial results. Your 
advisor suggests that you repeat some of her experiments to “test your hands” at 
the technique she had been using.  After running the experiments as written up in 
the experimental section of her communication for several weeks, you are unable 
to reproduce the data. You go through her notebooks and contact her via email in 
order to try and determine what is going wrong with your experiments. 
 
• Propose two situations/results from your actions (emailing and looking 
through notebooks) which would cause you be concerned about 
misconduct, and two situations which would not.  
(For example, if the student emails back that there is a minor technical issue that 
she forgot to record, and once you this into account, your experimental results are 
consistent with those in the paper, misconduct is unlikely).  
 
• For one of the situations in which misconduct may be an issue, propose 
both a reasonable course of action (who would you talk to, what would you 
say) and a less reasonable course of action for dealing with the situation.   
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stakeholders in this situation and suggested courses of action would entail the least harm 
to those involved. For example, some students initially found it reasonable to first take 
these concerns to a party outside the lab for a second opinion (in particular, a former 
advisor or other trusted faculty member). Upon further discussion, they realized that this 
option has potential consequences for both themselves and their current advisor.  They 
also pointed out that this solution fails the reversibility test, as they would be displeased 
with the advisor or former student broaching concerns about their work to one of their 
peers rather than to them.  
 Finally, case studies that involved conflicts but no overt ethical concerns were 
also included.  In one such case study (Box IV-4), students discussed a potential conflict 
that they might encounter where no ethical issues were at stake.  For this issue, students 
were quick to realize that even though there were no ethical concerns, they still needed to 
handle this situation in a professional and respectful manner.  Students pointed out that 
there were certain hierarchies they should follow in getting this problem resolved (ie, first 
talk to the safety officer, then the advisor, then the departmental head of safety) while 
still maintaining good relations with their advisor/lab-mates.  The students also discussed 








Box IV-4. Example of a case study presented to students.  Students were given an 
example of a situation where there were no concerns of ethical misconduct; however the 
situation still needed to be addressed in a courteous and respectful manner. 
 
 
G. Student Responses to the Data Interpretation Exercise 
  
As part of the 2010 module, a new data interpretation exercise was introduced.  
For this exercise, students were told that during their first rotation, one of their 
collaborators presented them with a series of data they had collected. The student who 
had collected this data then proposed a series of conclusions that could be drawn from 
this data.  The students were asked to determine which conclusions they would 
Case study- “Safety Issue” 
 
You are rotating in the lab you wanted to join. Your rotation project is 
going well, and you get along well with most of your lab-mates. However, the 
post-doc who works next to you often leaves flasks of the chemicals she is 
working with uncapped and on the bench. You have politely asked her to deal with 
them in an appropriate manner, but she has told you not to worry about it – none 
of them are especially toxic, and besides part of your job as a chemist is putting up 
with unpleasant smells.  
 
• Propose reasonable and unreasonable courses of action for each of the 
following conditions: 
 
1) The chemical is not particularly toxic (eg. acetone, ethyl acetate).  
2) The chemical is something potentially toxic or carcinogenic (eg. hexanes, 
dichloromethane). 
3) The chemical readily decomposes to hydrogen cyanide (volatile and lethal).  
4) Changes to any of the above, if the lab's advisor is out of town for an extended 
period of time.  
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accept/reject/amend based on the data presented.  They were also asked if any of the 
conclusions represented ethical concerns (see Section K).  When discussing the example 
shown in Box IV-5, the students had several thoughts on the validity of the conclusions 
presented.  Many students felt that conclusion A posed a problem because it stated that 
the reaction ran “smoothly” in 95% yield.  They believed that without a valid 
experimental reason as to why the other three trials gave such low yields, the use of the 
word “smoothly” was misleading.  Additionally, students noted that either conclusion C 
or D (using the mean or the median to represent the average value) would be a valid way 
to report the data, as long as the person reporting the data included which statistical 
method was used.  One common theme throughout this exercise was the need for 
transparency in discussing how raw data had been interpreted.  These exercises also 
served as excellent vehicles for discussing the differences between sloppy science, 
reasonable disagreements among professionals and misconduct.   
 As was the case with the case studies, we were pleased with the students’ ability 
to overlay the framework for solving ethical dilemmas onto the data interpretation 
exercises.  The students engaged with the material and applied some of the ideas that had 
been discussed to these diverse situations.  This indicates that the students are beginning 






Box IV-5. Example of a situation presented to students as part of the data interpretation 
exercise. 
 
H. Using Student Feedback to Improve the Curriculum  
 
At the end of the module each year, students were given a short questionnaire 
asking them to identify what they believed to be the most and least useful aspects of the 
module. The student responses from 2009 indicate that they found the module to 
generally be valuable and to provide interesting information.  In particular, the students 
appreciated the case studies and the emphasis placed on handling conflicts in a 
The following reaction was run with the reported yields: 
 
Which of the following conclusions would you 
accept/amend/reject? 
a) Using the most effective ligand (Ligand A) the reaction occurred 
smoothly in 95% yield. 
b) The reaction proceeded in higher yield with Ligand B (48% vs. 
33% with Ligand A).  
c) Ligand A (mean yield 46%) was more effective at facilitating the 
reaction than ligand B (mean yield 38%). 
d) Ligand B  (median yield 48%) was more effective at facilitating 
the reaction than ligand A (median yield 31%)  
Are there circumstances under which any of these are ethical 















professional manner.  Students also stated that they found the open question and answer 
sessions to be valuable. 
One prevalent suggestion that students gave was to decrease the amount of time 
allotted for small group discussions.  They stated that they found ten minutes to be 
adequate time for discussion (they had originally been asked to discuss each case for 
twenty minutes).  We agreed with the students comments in this area.  In the 2009 session, 
we had envisioned that we, the peer leaders, would have a greater opportunity to address 
the small groups.  In practice, however, there were too many students (~60) for us to be 
able to effectively reach all of the groups in a timely manner.   
These observations led to changes in the way the case studies were dealt with.  
First, we re-wrote the cases to give more written details so that the students could have a 
fuller small group discussion without relying on iterative input from the peer leaders.  
Second, in decreasing the time spent on the small group discussion, more time was 
opened up for another activity.  In order to fill this gap, the data interpretation exercise 
was created and incorporated.   
The course evaluations from the 2010 indicate that students again found the case 
studies to be useful.  As there were no comments about the time allotted for small group 
discussions, we concluded that ten minutes of discussion was sufficient.  The students 
also commented that they found the data interpretation exercises to be useful and 
interesting.   
 
I. Response from the Chemical Community 
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In evaluating the uniqueness of this module, we wanted to gauge the response by 
the chemical community.  We presented this work at the Spring 2010 National ACS 
conference where it was met with positive comments from members of the chemical 
education community.20  This work was also featured as part of the October 2010 ACS 
graduate student bulletin in an article focused on research ethics in graduate school.21  
This positive response indicates that a peer-led approach to teaching research ethics is a 
unique and valuable addition to current methods for accomplishing this task.  
 
J. Conclusions and Future Directions
 
 
Recent events have highlighted the need for formal ethics training for all 
researchers.3,4,5  Graduate students are a key audience for this type of training as they are 
often carrying out full-time research for the first time in their lives.  A peer-led approach 
to teaching research ethics was developed for use as part of the graduate student 
orientation curriculum.  It was postulated that senior graduate students would provide a 
valuable perspective in teaching research ethics to their junior colleagues as they have 
unique insight into the issues facing current graduate students.  It was also postulated that 
using senior graduate students as instructors would send the message to the incoming 
students that research ethics is important to their peer group, and thus should be 
important to them.  This course relied heavily on the use of case-studies and a data 
interpretation exercise as a means for discussing complex ethical dilemmas.  The case 
studies and data interpretation exercises were designed by the peer-leaders to reflect real-
life conundrums that first and second year graduate students were likely to face.  The 
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effectiveness of this module was then gauged by student responses during large group 
discussion.  As the students’ responses during the large group discussions incorporated 
many of the ideas that were presented earlier in the module, it can be concluded that the 
students were beginning to grasp the complexities inherent in ethical decision making.  
Additionally, responses from student evaluations and the chemical community at large 
indicate that the peer-led module is a valuable addition to the curriculum for teaching 
research ethics. 
The future of research ethics training in the Chemistry Department at the 
University of Michigan will be heavily influenced by the work described here.  Starting 
in the Fall 2011 semester, a 1-credit research ethics course will be taught to chemistry 
department researchers.  This course will be designed and initially co-taught by myself 
and Dr. Fierke and will likely incorporate many of the positive aspects of the peer-led 
module including the use of case studies as vehicles for discussion and a focus on 
immediacy, practicality and identifying resources who can be helpful in advising students 
facing an ethical dilemma.  It is hoped that senior graduate students in the chemistry 
department will contribute ideas for case studies based on their experiences so that this 
course will adapt to an ever changing research climate.   
Additionally, in the long term, a graduate student instructor (GSI) could be 
assigned to this course so that senior graduate students would have a direct and continued 
involvement in the planning and implementation of teaching research ethics.  Recitation 
sections, which are traditionally taught by GSIs, would be an optimal place for senior 
students to interact with the younger students without a faculty member present.  
Alternatively, students who have a expressed an interest in teaching as a career and are 
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involved in the GAANN program could work with the faculty member(s) teaching this 
course to maintain a student presence and to give insight into the every day demands and 
situations facing current students. 
 Additionally, it is hoped that ethics training could be more deeply incorporated 
into the research environment in the chemistry department.  While a formal ethics course 
is certainly valuable, it will not be sufficient to address all student concerns regarding 
research ethics.  This is especially true as the nature of ethical concerns students face tend 
to change during the course of graduate school.  For example, as students become more 
independent and take on mentorship roles, they are exposed to a variety of concerns such 
as authorship issues, ethical considerations for engaging in a mentoring relationship, and 
concerns about forming collaborations that younger students generally will not contend 
with.  Designated senior peer-leaders could act as mediators for formal or informal 
discussions among other senior graduate students to address ethical issues that arise 
during the course of research.  This would foster an open environment for discussing 
ethical concerns thus increasing the likelihood that ethical dilemmas will be addressed in 
a productive manner. 
 Finally, an effective means for tracking and measuring how effectively students 
deal with ethical concerns they face outside of the classroom should be established.  With 
the first class of students who were exposed to the peer-led module reaching candidacy in 
2011, it would be valuable to chart what effects this module had on student thinking and 
attitudes as they progressed through their first two years of graduate school.  A follow-up 
survey should be conducted with students in the summer of their second year (soon after 
most students finish candidacy) to determine which aspects of this course they found 
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valuable.  Specifically, it should be noted how students approached any ethical dilemmas 
they may have encountered.   
As a more long-term way of charting the effects of this course, one could envision 
discussions with senior faculty members, particularly those who have served or are 
serving on the Graduate Committee.  If formal training in research ethics does elicit a 
shift in how students approach ethical decisions, faculty members who have mentored 
several generations of students should note a difference in attitudes of these younger 
students. 
 
K. Course Material 
 K.1. Case Studies 
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Case Study #1: Rotation Project 
 
You are several weeks into a rotation in the research lab that you would like to 
join. Although the lab's research focus interests you, the senior graduate student you 
are working with is having you run reactions for his methodology project according 
to a protocol that he has already developed and using substrates that he has already 
decided upon.   
This lab only will only be accepting a single new student at the end of the year, 
and has already had three rotators. You do not have much direct interaction with the 
lab's advisor, and other lab members have told you that whether or not you are 
selected to join the lab will depend almost entirely on the presentation you give at the 
end of your rotation. This presentation is given to the entire group, including the 
advisor, and you will be expected to present and discuss the work you have 
completed during your rotation. You are concerned that your lack of creative input in 
your project will negatively affect the quality of your presentation and your chances 
at being accepted into this lab.  
 
• Are there circumstances under which this would not be a problem (describe 
them)? How would you go about determining whether or not this is the case? 
  
• Assuming that it turns out to be a problem, propose both a reasonable and 




Case Study #3: Authorship 
 
As part of your rotation, you run an experiment to identify an unknown protein by 
MS/MS. You perform the technical aspects of the experiment, under the supervision 
of your rotation mentor. Your mentor also helps you work up and analyze the data. 
Based on these results, the protein is tentatively identified. After your rotation ends, 
you hear that the group is writing up a paper in which the identification of this protein 
is used as supporting evidence for a proposed regulatory mechanism.  
 
• Under what circumstances is your omission from the authorship list 
reasonable? Under what circumstances is it a problem? If it is a problem, how 
could you go about addressing this? 
 
• One of the key questions is how significant of a contribution you made to the 
experiments resulting in the initial identification of this protein. Propose 
factors that (1) would clearly indicate that you made a significant contribution 
to the project, (2) would clearly indicate that you did not make a significant 





Case Study #6: Inspiration 
 
You are finishing up a rotation in the lab you intend to join, and have an 
upcoming meeting with your future advisor in which the two of you will discuss 
potential thesis projects.  All during your rotation, you had been thinking about a 
project based on a future direction presented by a graduating PhD student in the lab 
you worked in as an undergraduate.  You think this project fits in nicely with what 
your grad lab is doing, builds on your current skills and interests, and will be exciting 
enough to send out as a JACS or perhaps a PNAS paper if it works. You are sure that 
your new advisor would be as excited about this idea as you are.  
 
• What practical and ethical concerns should you have about proposing this 
project?  
 
• For the following situations, propose both a reasonable and unreasonable 
course of action.  
1) Your undergraduate advisor is retiring and you know they are no longer 
carrying out research. 
 
2) You know the project is intended as an REU project for the next summer. 
  
3) The original idea for this project came from either an experimental result   
      of yours (as an undergraduate) or a conversation between you and your  













K.2. Data Interpretation Exercise  
 
 




Which of the following conclusions would 
you accept/amend/reject? 
a) Based on graph 1, drug B is more potent 
than drug A.  
b) Removing the off-line data point at X=1 
for drug B produces graph 2. Graph 2 is 
more appropriate for publication.  
Are there circumstances under which any of 
these are ethical problems?    
 
Graph 1  




















The ability of a 'treatment' (drug, RNAi, etc) to alter expression of protein 
X was determined by Western Blot 
Which of the following conclusions would you 
accept/amend/reject? 
a) Treatment A reduces expression of protein X 
with an EC50 of approximately 100 nM. 
b) Treatment B induces a ~20% increase in 
expression of protein X.  
c) Treatment C reduces expression of protein X. 
Are there circumstances under which any of these 
are ethical problems?   
a)  
b)  
This control may be omitted initially 
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A.1. Synthesizing and Identifying Small Molecule Probes for Targeting 
Transcriptional Co-factors  
 
 
The first part of my doctoral work focused on synthesizing and identifying small 
molecule probes for targeting transcriptional co-factors.  As endogenous transcriptional 
activators exhibit a multi-partner binding profile, it is necessary to synthesize a diverse 
library of small molecules to modulate these interactions.
1,2,3
  In order to swiftly obtain a 
diverse array of small molecules that can be screened for their ability to modulate 
transcription, building block molecules that can be further transformed to a variety of 
more complex structures should be employed.   
The allenamide scaffold is one such building block that has been used in the 
synthesis of a variety of small heterocycles.
4,5,6,7,8,9  
The work presented here includes a 
novel methodology for the facile synthesis of highly substituted allenamides.  This 
methodology, which can be accomplished in few synthetic steps from readily available 
starting materials, allows for the formation of mono-, di- and tri-substituted allenamides 
in good yields.  The methodology presented also allows for the formation of 
enantiomerically enriched allenamides provided that an enantioenriched propargylic 
alcohol is employed in the first step.  It was discovered that due to the unique electronic 
nature of the allene system, these allenamides display a reactivity pattern more similar to 
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electron-neutral allenes than to other, more electron-rich allenamides.  These allenamides 
were employed in the synthesis of diverse secondary structures.  It is therefore likely that 
these allenamides could serve as a scaffold for the formation of highly substituted 
heterocycles that could be screened for their ability to modulate transcription. 
My thesis work also focused on using small molecule probes to identify protein 
co-factors that are essential in maintaining self-renewal in cancer initiating cells (CICs).  
It was discovered that transcription driven by Nanog (a protein that is over-expressed in 
CICs and is associated with maintenance of pluripotency and self-renewal) is dependent 
on the co-factor p300 respectively but not its paralog CBP.  In order to elucidate which 
domain(s) of p300 were essential for Nanog-driven transcription, two synthetic probes 
(an amphipathic isoxazolidine and a hydrogen bond surrogate) that bind specifically to 
the KIX and CH1 domains of p300 were tested for their ability to inhibit Nanog-driven 
gene expression.  It was found that both probes caused a reduction in transcription, 
indicating that both the KIX and CH1 domains of p300 are involved in Nanog-driven 
gene expression.  
 In order to examine if disrupting the functionality of these domains was sufficient 
to elicit a change in the ability of CICs to self-renew, CICs were dosed with amphipathic 
isoxazolidine and relative viabilities were measured.  It was found that at higher doses, 
the amphipathic isoxazolidine had a cytostatic effect on embryonal carcinoma cells (a 
CIC model system).  Additionally, when the molecule was dosed into a mammalian cell 
line that contained a mixture of differentiated bulk tumor cells and undifferentiated CICs, 
a reduction in the CIC population but not the bulk tumor cell population was observed.  
These findings indicate that the KIX domain of p300 is necessary for Nanog-driven gene 
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expression and that disruption of KIX function is sufficient to decrease self-renewal in 
CICs.  These findings also indicate that disruption of Nanog functionality could be a 
novel target for the development of therapeutics targeted against CICs, which as of yet 
have proven to be largely resistant to traditional chemotherapeutics. 
 
A.2. Design and Implementation of a Peer-Led Practical Research Ethics 
Module for Teaching Graduate Research Ethics 
 
 
 The need for formal training in research ethics has been well established.
10,11
  It 
has been noted that formal education in research ethics is most effective when it is taught 
in a creative manner emphasizing practicality and support networks in addressing ethical 
concerns.
12
  To this end, a portion of my thesis work focused on designing and 
implementing a peer-led practical research ethics module for teaching graduate research 
ethics.  This module aimed to provide incoming graduate students with the knowledge 
they would need to address complex ethical concerns they were likely to face in their 
early graduate careers.  In order to facilitate discussions, several case studies were 
designed by the peer-leaders addressing ethical dilemmas faced by the 2006 and 2007 
chemistry department cohorts.  The incoming students discussed these case studies in 
both large and small groups.  The student responses given during the large group 
discussions incorporated many of the topics discussed on effective ways to address 
ethical concerns.  These responses indicate that the module was successful in giving 
students the tools they need to address complex ethical issues.  Responses given in the 
course evaluation survey indicate that students found the course to be useful.  
Additionally, the responses from the chemical community indicate that the peer-led 
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method for teaching research ethics is a valuable addition to the current methods for 
teaching research ethics to graduate students. 
 
B. Future Directions 




Studies with synthetic ligands of the KIX and CH1 domains of p300 indicate that 
these domains are necessary for Nanog-driven gene expression.  However, it is possible 
that other p300 domains may play a role in this process.  In order to test this, each of the 
individual domains of p300 will be over-expressed in cellulo.  These over-expressed 
domains should effectively compete with p300 for endogenous binding partners, 
therefore disrupting the ability of p300 to act as a bridge between a DNA-bound activator 
and the transcriptional machinery (Figure V-1).   By mapping out the p300 domains 
involved in Nanog-driven gene expression, further synthetic probes can then be designed 
to bind to each of the relevant domains.  These probes will be tested for their ability to 
bind p300.  Probes that are found to bind p300 will then be dosed into either a head a 
neck squamous cell carcinoma (HSNCC) or embryonal carcinoma (EC) cell line.  Post-
treatment, the levels of messenger RNA (mRNA) levels of Nanog-regulated genes (ex. 
Nanog, Oct4, Sox2, EBAF1, etc) will by measured by quantitative polymerase chain 
reaction (qPCR) as a means of determining the in cellulo efficacy of these molecules in 
inhibiting endogenous Nanog-driven gene expression. 
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Figure V-1. Determining the reliance of Nanog –driven gene expression on individual 
domains of p300.  Individual domains of p300 (here represented as a purple rounded 
wedge) will be over-expressed in cells.  Domains that bind to the Nanog TAD (here a red 
square) compete for binding with endogenous p300.  This competition causes a decrease 
in the level of Nanog-driven transcription. 
 
 
B.2. Determining the Effects of Inhibiting p300 Functionality in Maintaining 
Pluripotency and Self-Renewal   
 
 
 Results derived from a reporter context will provide valuable insight into the 
domains of p300 necessary for Nanog-driven gene expression.  It will be necessary to 
determine if perturbing the functionality of p300 will have an effect on the maintenance 
of self-renewal.  To this end, the synthetic molecules will be dosed into HNSCC cells to 
determine their ability to reduce CIC self-renewal as measured by fluorescence activated 
cell sorting (FACS) or tumor sphere formation studies.  Compounds that are able to 
selectively inhibit the ability of CICs to self renew will be used in further studies.   
Additional studies will be carried out to determine if synthetic ligands of p300 
have the ability to disrupt pluripotency in CICs.  These studies will be carried out in an 
embryonal carcinoma cell line, NCCIT, which has been previously used as a model CIC 
system.  NCCIT cells will be dosed with synthetic ligands that bind specific domains of 
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p300, or short hairpin RNA (shRNA) targeting p300.  The messenger RNA (mRNA) 
levels of genes associated with differentiated (ex. lineage markers such as CDX2, 
GATA4, BRACHYURY, and MAP2) and undifferentiated (ex. Nanog, Sox2, Oct4, 
ALDH) cellular phenotypes will be monitored for treated and controlled cells.
13
  
Compounds that elicit expression of relatively higher levels of differentiation markers 
relative to pluripotency markers will be selected for further testing. 
In addition to bridging functionality, p300 also has histone acteyltransferase 
(HAT) activity.  Studies carried out by Han and co-workers show that molecules capable 
of inhibiting histone deacetylation cause a loss of pluripotency and self-renewal in EC 
cells.
13
  Additionally, it has been shown in embryonic stem cells (ESCs) that p300 plays a 
role in Nanog-driven gene expression by acetylating a distal regulatory region of the 
Nanog promoter.
14
  It is therefore likely that a highly optimized level of histone 
acetylation must be achieved for cells to remain in a pluripotent state.  It is possible that 
disrupting the HAT activity of p300 could lead to a decrease in CIC pluripotency and 
self-renewal.  Synthetic molecules that specifically inhibit the HAT activity of p300 and 
CBP relative to other proteins with HAT capabilities have been discovered in the Cole 
laboratories.
15,16
  These compounds will be tested by the aforementioned methods to 
measure their ability to disrupt self-renewal capabilities and pluripotency in CICs, thus 
determining if p300 HAT activity is necessary for the maintenance of these 
characteristics in CICs. 
 
B.3. Determining the In Vivo Functionality of p300 Ligands  
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In order to determine the ability of p300 ligands to affectively target CICs in vivo, 
HNSCC cells with constitutive luciferase expression will be implanted into NOD/SCID 
mice.  After initial tumors have formed, the mice will be intravenously dosed with p300 
ligands that were effective in cellulo at inhibiting pluripotency and self-renewal in CICs.  
The growth of the initial tumor and the extent of lung metastasis will be monitored for 4-
6 weeks.  It is likely that some of the probes used in cell culture will have to be modified 
to maximize their in vivo effectiveness. 
At the termination of the experiment, the remaining tumor bulk will be analyzed 
for its CIC content.  Additionally, normal stem cells will be examined in mice treated 
with compounds versus control mice to determine if disrupting p300 functionality will 
selectively affect CICs rather than normal stem cells.  While normal stem cells and CICs 
share many similar biochemical characteristics, there are limited examples of therapeutics 
that are able to target CICs without damaging normal stem cells.
17
  If these molecules are 
able to selectively target CICs in vivo, it would provide evidence that targeting the 
functionality of p300 is a tractable means for eliminating this cell population.  This would 
be a large advancement in the field of cancer research as cancer initiating cells have 
proven to be resistant to traditional chemotherapeutics and ionizing radiation.
18,19
   
 
B.4. Synergistic Approach for Targeting CICs. 
 
My thesis work has focused on the transcription factors that are responsible for 
maintaining pluripotency and self-renewal in CICs.  Currently, a small number of 
potential therapeutics have been identified that target pathways and cell surface markers 
that are present in CICs and not in bulk tumor cells.  As some of these therapeutics have 
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entered phase-III clinical trials, it is likely that at least a subset of them will prove to be 
effective therapies for treating poorly differentiated cancers in the clinic.
17
  It is possible, 
however, that these therapies in isolation may be insufficient to fully eliminate the CIC 
population of a given cancer.  It is therefore necessary to devise combinatorial 
approaches to target multiple aspects of the CIC self-renewal and pluripotency pathways.   
Current, unpublished work in the Mapp laboratories is focused on using a 
combinatorial approach to inhibit the growth of erbB2 positive breast cancer cells.  In 
these studies, it was found that combining a small molecule ligand capable of modulating 
transcription of the erbB2 gene with therapeutics that are currently used in the clinic to 
target positions in related pathways caused a synergistic decrease in the viability of  
erbB2 + cancer cells.  These results indicate that simultaneously inhibiting transcription 
of a certain gene and key points in related pathways may prove to be a tractable 
therapeutic strategy for treating cancers.  The synthetic ligands of p300 found elicit a 
decrease in the ability of CICs to self-renew and maintain pluripotency should therefore 
be tested in tandem with known inhibitors of CIC-specific pathways for their ability to 
synergistically affect pluripotency and self-renewal of these cells.  Also, combinations of 
small molecule transcription inhibitors that bind to distinct domains of p300 should be 
tested to determine if they are able to synergistically inhibit p300 functionality.  Similarly, 
combination strategies involving treatment with active p300 ligands and traditional 
chemotherapeutics designed to treat bulk tumor cells should be tested for their ability to 
completely eliminate tumors. 
 




  B.5.A Synthesizing Small Molecules from the Allenamide Scaffold 
 
 Allenamides have proven to be quite versatile as a substrate for the formation of a 
variety of highly substituted heterocycles.  Allenamides are therefore a valuable building 
block scaffold for the synthesis of a variety of small molecules that could act as ligands 
for transcription co-factors.  The allenamides synthesized in the methodology reported in 
this thesis differ from previously synthesized allenamides in that the allene moiety is less 
electron rich.  This difference in electronics causes these allenamides to adopt a reactivity 
pattern analogous to hydrocarbon allenes rather than previously reported allenamides.  As 
such, they could be used as substrates in further reactions that have previously been 
demonstrated to work with allenes.
20,21
  These reactions could lead to the formation of 
molecules that could be screened for their ability to bind to transcription co-factors 
(Figure V-2).  Additionally, as these heterocycles are rather small, they could be used 








Figure V-2. Small molecules that could potentially be synthesized from an electron-
neutral allenamide.  Molecules of the nature shown on the left have been previously 
synthesized from an allene starting material.  Due to the unique electronic nature of the 
allenamides discussed in this thesis, it is likely that they could be used as substrates in 
these types of reactions to produce a variety of highly substituted small molecules that 
could be screened for their ability to modulate transcription. 
  
B.5.B. High Throughput Screens for Identifying Natural Product 
Ligands 
 
 One method that is currently being investigated for identifying novel ligands of 
p300/CBP is the screening of natural product libraries.  From an initial screen of 67,000 
compounds and natural product extracts, researchers in the Mapp laboratories have 
identified a class of known natural products, the depsides, which are capable of inhibiting 
the interaction of the KIX domain of CBP with one of its endogenous ligands (MLL).  
After initial identification, one molecule, sekikaic acid, was taken on to additional studies. 
Using fluorescence polarization (FP) and HSQC NMR experiments, it was determined 
that sekikaic acid is capable of binding in a way that affects both ligand binding domains 
of  KIX (Figure V-3).  This initial finding highlights the utility of this approach in 
identifying potential small molecule ligands of transcription co-factors.  As the other 
compounds that were identified as hits in the original screen were also depsides, non-
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natural molecules based on this scaffold could also be synthesized to and tested for their 
ability to bind to the KIX domain.    
 
Figure V-3. Structure of sekikaic acid.  Sekikaic acid is a natural product that was 
discovered in the Mapp laboratories to bind to the KIX domain of CBP. 
 
 Additional screens on these and other libraries could be carried out using other 
domains of CBP to identify small molecule ligands capable of binding to them.  This will 
be especially useful for identifying small molecule ligands of CBP domains, such as the 
CH2 domain, which currently have no known inhibitors. 
 
B.6. Improvements to Current Methodologies for Teaching Research Ethics 
to Graduate Students 
 
 
 The peer-led method for teaching research ethics has proven to be an effective 
means for teaching research ethics to first year graduate students in chemistry at the 
University of Michigan.  The use of peer-leaders in teaching research ethics should be 
expanded to other departments at the University of Michigan and in other chemistry 
departments across the nation.  One way to accomplish a change in the way that ethics is 
taught in chemistry departments is through partnership with the ACS.  By working with 
the ACS Committee on Ethics, it may be possible to include more graduate students, 
post-docs and undergraduates directly in developing curriculum for teaching research 
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Design and Synthesis of a Focused Library of Spirooxindoles to Modulate the 





 Activated transcription is a complicated event that requires the interactions of 
many different proteins.  One type interaction that is of specific interest to the Mapp 
laboratories is the interaction of DNA-bound activators with their co-factors in the 
transcriptional machinery.  The co-factors p300 and its paralog the Creb Binding Protein 
(CBP) have been shown to bind to a number of different transcription factors.  In order to 
better understand the roles of these large, multi-domain proteins, small molecules that 
bind to specific domains can be employed.  To this end, a small focused library of 
spirooxindoles was synthesized.  The spirooxindole scaffold was chosen as 
spirooxindoles are readily synthesized and highly functionalizable.  The library that was 
synthesized for this work was designed to bind to the CH1 domain of p300/CBP.  In 
cellulo studies indicate that four of the spirooxindoles were able to disrupt the 
functionality of an activator known to bind to the CH1 domain of p300/CBP (HIF-1α).  
These compounds also disrupted the functionality of three other amphipathic activators 
that do not interact with the CH1 domain of p300/CBP.  This indicates that these small 
molecules do not specifically inhibit the function of the CH1 domain; however, they may 





 B.1. The role of CBP/p300 in Activated Transcription 
 
 
 Activated transcription is initiated by a class of proteins known as transcriptional 
activators.  These activators are modular in nature consisting of a DNA-binding domain 
(DBD) and a transcriptional activation domain (TAD).  Once the DBD binds to a specific 
site on DNA, the TAD then makes contacts with other members of the transcriptional 
machinery that are necessary for the recruitment of RNA Polymerase II (RNA Pol II).1  
The Creb-Binding Protein (CBP) and its paralog p300 have been shown to contact 
several transcriptional activators that are implicated in disease states.2,3  Additionally, 
there is increasing evidence the p300 may play a role in the maintenance of pluripotency 
and self-renewal in cancer imitating cells (CICs).4,5  In order to better study the roles 
CBP/p300 play in transcription, small molecule ligands that bind specific domains of 
these proteins can be employed.   
 The CH1 domain of CBP/p300 may play an important role in the maintenance of 
pluripotency and self-renewal in CICs.6  Additionally, there is evidence that the binding 
of the CH1 domain to the hypoxia inducible factor-1α (HIF-1α) is necessary for survival 
of solid tumors and that disruption of this interaction could be sufficient to cause a 
decrease in the size of such tumors.7  As such, synthetic probes that perturb the function 
of the CH1 domain could provide valuable insight into the underlying cellular 
mechanisms regulating tumor maintenance and growth. 
 
 B.2. Small Molecule Ligands of the CH1 Domain of p300/CBP 
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In 2006, when the work that will be discussed in this appendix was started, there 
was only one synthetic molecule that was able to effectively bind the CH1 domain of 
p300/CBP.  This small molecule, the fungal metabolite chetomin, was first found to bind 
to the CH1 domain by Livingston and co-workers as a part of a high throughput screen of 
natural products (Figure A-1).8  Chetomin proved to bind the p300 CH1 domain with 
submicromolar affinity.  However, there is currently no known synthetic route to 



















Figure A-1. Structure of chetomin. 
 
B.3. Designing Small Molecule Ligands of the CH1 Domain of p300/CBP 
 
Most of the endogenous TADs that bind the CH1 domain of p300/CBP are 
amphipathic in nature containing a mix of both polar and hydrophobic residues.1  Many 
amphipathic TADs are unstructured in solution but fold into α-helices upon binding to 
co-activator targets with the hydrophobic residues providing the bulk of the contact with 
the target protein.9  The Mapp laboratories had previously found that amphipatic, 
conformationally constrained small molecules can effectively bind to members of the 
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transcriptional machinery.10,11,12,13  In order to expand the repertoire of available small 
molecules that can act as a probes for perturbing specific transcription events, a small 
focused library based on the spirooxindole scaffold was developed.  This scaffold was 
chosen because spirooxindoles are readily synthesized, highly functionalizable and offer 
a radial, helix-like display of functionality (Figure A-2).14  Additionally, spirooxindole 
derivatives have been shown to effectively inhibit the binding of an amphipathic TAD 
(p53) to its masking partner MDM2. 15,16  
 
Figure A-2. Spriooxindole scaffold.  Sites on the molecule that could be modified to 
introduce additional functionality are indicated. 
 
 
C. Synthesis of a Focused Library of Spirooxindoles 
 
The parent spirooxindole for the library was synthesized in good yield (86%) via 
a route developed by Sebahar and co-workers (Figure A-3).17  Several sites on the 
molecule were identified as potential locations for appending additional functionality 
(Figure A-2).  Opening the lactone of the spirooxindole proved to be an accessible way to 
introduce modifications and the ring-opening reactions proceeded in good to moderate 
yields (78-53%) (Figure A-4).   A number of amines were used to introduce straight-
chain and branched hydrophobic functionality at this position.  These types of 
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hydrophobic residues were included as it is known that one of the native CH1 ligands, 
HIF-1α, relies on three key leucine residues for binding to the CH1 domain.18  It was 
believed that increasing the hydrophobicity of the molecule and including functional 
groups that would mimic the endogenous leucines would be advantageous.    
 
 
Figure A-3. Synthetic route for the formation of spirooxindole A-1.   Conditions: 1) 
isatin (1.0 equiv), methyl (triphenylphosphoranylidene) acetate (1.0 equiv) in acetic acid, 
90 °C, 6 hours. 2) Indole (1.5 equiv), morpholine (1.0 equiv), aldehyde (1.2 equiv) 
molecular sieves, in toluene, 60 °C, 1 hour. 
 
A subset of the molecules that were made for the initial library were further 
modified by deprotecting the pyrrolidine nitrogen via a radical reaction with cerium 
ammonium nitrate (CAN) (Figure A-4).  This was done to investigate the best balance of 
hydrophobicity and size for synthesizing effective ligands.  The resultant molecules were 
become quite unstable and they usually decomposed completely on the bench top within 
1-2 days of synthesis.   
Attempts to modify the parent spirooxindole at other locations were met with 
limited success.  It is possible to introduce phenyl and methoxy-phenyl substituents in 
place of the isobutyl group simply by using the corresponding aldehyde in the original 
cycloaddtion (Figure A-4).  These molecules were then subjected to the same ring-
opening conditions as the original parent scaffold.  Attempts to alter the ester moiety 





Figure A-4. Spirooxindole library.  These spirooxindoles were synthesized to be 
screened for their ability to inhibit the functionality of the CH1 domain of p300/CBP.  
Differences in functionality are highlighted in red.  The parent spirooxindoles were 
synthesized as stated in Figure A-2.  Conditions for ring opening reaction: spirooxindole 
(1.0 equiv), primary amine (1.5.0 equiv), Et3N (1.5.0 equiv) in THF, rt, overnight.  
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Conditions for the deprotection of the nitrogen: ring opened spriooxindole (1.0 equiv), 
CAN (2.0 equiv) in MeCN/H2O, rt, 15 mins.  Reported yields are of the final synthetic 
step required to form the structure. 
 
D. Determining the Ability of Spirooxindoles to Inhibit Activator·Co-activator 
Interactions 
 
 A competitive inhibition experiment was conducted with the minimal activation 
domain of HIF-1α (a known endogenous binding partner of the CH1 domain of 
p300/CBP7,16) and the synthesized spirooxindoles to assess whether these compounds 
bound overlapping targets.  A former post-doc in the Mapp laboratories, Dr. J.P. 
Desaulniers, synthesized a plasmid that encoded for the Gal4 DBD fused to the minimal 
HIF-1α activation domain (amino acids 786-826) to be used in these experiments.  For 
these experiments, Dr. Desaulniers transfected HeLa cells with this plasmid causing the 
cells to express the fusion protein.  Upon binding to the Firefly luciferase reporter 
plasmid, the HIF-1α TAD recruited its target proteins (including p300/CBP) and 
upregulated transcription of the reporter gene.  The inhibition of the TAD·co-factor 
interactions by the small molecules would cause a decrease in reporter gene expression.  
This is quantified by luminescence of Firefly luciferase, compared to Renilla luciferase 
(used as a transfection control).  Four of the spirooxindoles assayed caused a decrease in 






























Figure A-5. Spirooxindoles that inhibited HIF-1α-driven transcription.  The four 
spirooxindoles shown caused a decrease in activation of a HIF-1α-driven reporter system.  
Briefly, HeLa cells were transfected with a plasmid expressing the Gal4-HIF-1α minimal 
TAD fusion protein, a second plasmid bearing five Gal4-binding sites upstream of a 
Firefly luciferase reporter gene, and a third plasmid expressing Renilla luciferase as a 
transfection control.  Compound was added to the cells as a DMSO solution 3 hours after 
transfection to a final DMSO concentration of 1% (v/v).  The Firefly and Renilla 
luciferase activities were measured 24 hours after compound addition using the Promega 
Dual Luciferase Kit.  Fold activation was determined at each concentration by first 
dividing the Firefly luciferase by the Renilla luciferase.  This value was then divided by 
the activity observed at 0.1 µM compound.  Each value is the mean of three independent 
experiments with the indicated error (SDOM).  
 
 To determine if these compounds bound specifically to the CH1 domain of 
p300/CBP, competition assays between other TADs known to interact with other proteins 
besides the CH1 domain were performed by a colleague Jonas Højfeldt.  Plasmids 
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encoding for Gal4-fusions of these activation domains were made and this assay was 
carried out analogously to HIF-1α competition assay.  It was found that the compounds 
inhibited the expression of all of the tested activators, indicating that these compounds do 
not specifically bind to the CH1 domain of p300/CBP (Figure A-6).  These compounds 
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Figure A-6. Spirooxindoles do not specifically inhibit the function of the CH1 domain of 
p300/CBP.  Spirooxindoles found to inhibit HIF-1α functionality were assayed for their 
ability to inhibit the functionality of other amphipathic activators.  These compounds 
inhibited activation driven by these activators to similar levels as they did HIF-1α 
indicating they do not specifically affect the function of the CH1 domain of p300/CBP.  
Experiments were carried out as described in Figure A-4 with the exception that the 





 A focused library of spirooxindoles was synthesized and assayed for its ability to 
inhibit the interactions of HIF-1α and its endogenous co-factor the CH1 domain of 
p300/CBP.  The spirooxindole scaffold was originally chosen for this work as it is highly 
functionalizable and allows for a radial display of functionality.  Of the 11 spirooxindoles 
synthesized, four of them were able to down-regulate the expression of a luciferase 
reporter gene regulated by a fusion protein of the Gal4-DBD with minimal TAD of HIF-
1α.  These compounds were also found to inhibit the functionality of three other 
amphipathic activators that bind to distinct co-factors.  This indicates that the 
spirooxindoles do not specifically inhibit the functionality of the CH1 domain of 
p300/CBP.  These compounds may be used in the future as global inhibitors of the 
function of amphipathic activators.  Additionally, it is possible that these compounds 
disrupt the interaction of a distinct set of proteins necessary for the transcription of all 
four of the tested activators and could prove to be useful as probes for understanding the 




 Unless otherwise noted, starting materials were obtained from commercial 
suppliers and used without further purification.  THF and toluene were dried by passage 
though activated alumina columns.  Purification by flash chromatography was carried out 
with E. Merck Silica Gel 60 (230-400 mesh) according to the procedure of Still, Kahn, 
and Mitra.19  All reactions involving air- or moisture-sensitive compounds were 
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performed under a nitrogen atmosphere.  (E)-methyl 2-(2-oxoindolin-3-ylidene)acetate20 
and (5R,6S)-5,6-diphenyl-1,3-oxazinan-2-one21 were prepared according to literature 
procedures. 1H NMR spectra were recorded in CDCl3 at 400 or 500 MHz. 
General procedure for spirooxindole synthesis 
 
 To toluene (80 mL) was added (E)-methyl 2-(2-oxoindolin-3-ylidene)acetate (4.8 
mmol, 1.5 equiv), (5R,6S)-5,6-diphenyl-1,3-oxazinan-2-one (7.2 mmol, 1.0 equiv), 
aldehyde (5.8 mmol, 1.2 equiv) and 3 Å activated molecular sieves (0.9g).  The solution 
was heated to 60 °C and stirred for 1 hour with monitoring by TLC (3:1 hexanes/ethyl 
acetate).  The toluene was removed under vacuum and the crude mixture was subjected to 
flash chromatography (3:1 hexanes/ethyl acetate to 1:1 hexanes/ethyl acetate) to provide 
the product spirooxindole. 
General procedure for opening the spirooxindole lactone 
 
 To THF (1.0 mL) spirooxindole (0.1 mmol, 1.0 equiv) primary amine (1.5 mmol, 
1.5 equiv) and NEt3 (1.5 mmol, 1.5 equiv) were added.  The reaction was stirred at room 
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temperature overnight.  The THF was removed under vacuum and the crude mixture was 
subjected to flash chromatography (3:2 hexanes/ethyl acetate). 
General procedure for the nitrogen deprotection 
 
 To MeCN (0.6 mL) and water (0.3 mL) spirooxindole (0.06 mmol, 1.0 equiv) and 
CAN (0.1 mmol, 2.0 equiv) were added.  The reaction was stirred at room temperature 
for 15 minutes with monitoring by TLC (3:2 hexanes/ethyl acetate).  The reaction was 
quenched with water, extracted with EtOAc (3x, 1 mL), dried over Na2SO4, filtered and 
concentrated under vacuum.  The crude mixture was subjected to flash chromatography 






Prepared via the general procedure in 86% yield as a pale yellow solid. 1H NMR: δ  0.59 
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(d, J = 6.4 Hz, 3H), 0.73 (d, J = 6.0 Hz, 3H), 1.0-1.1 (m, 1H), 1.2-1.3 (m, 2H), 3.2 (s, 3H), 
3.8 (dd, J = 3.2, 7.8, 1H), 4.0 (d, J = 8.0 Hz, 1H), 4.5 (d, J = 3.2 Hz, 1H), 4.9 (d, J = 8.0 
Hz, 1H), 6.1 (d, J = 3.2 Hz, 1H), 6.9 (d, J = 7.6 Hz, 1H), 7.0 (td, J = 7.6, 0.8 Hz, 1H), 















Prepared via the general procedure in 70% yield as a white solid. 1H NMR: δ  0.56 (d, J = 
7.0 Hz, 3H), 0.62 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 7.0 Hz, 6H), 1.1 (t, J = 7.0 Hz, 1H), 
1.5-1.6 (m, 2H) 1.7 (sept, J = 7.0 Hz, 1H), 2.9-3.0 (m, 1H), 3.1-3.2 (m, 1H) 3.2 (s, 3H), 
3.7 (d, J = 9.0 Hz, 1H), 3.8 (d, J = 9.0 Hz, 1H), 4.3 (dd, J = 3.2, 7.0 Hz, 1H), 4.6 (d, J = 
5.0 Hz, 1H), 4.9 (s, 1H), 5.4 (d, J = 5.0 Hz, 1H), 5.8 (t, J = 5.0 Hz, 1H), 6.9 (t, J = 7.5 Hz, 
2H), 7.0 (t, J =  7.5 Hz, 1H), 7.1 (t, J = 7.5 Hz, 1H), 7.2-7.3 (m, 6H), 7.4 (d, J = 7.0 Hz, 
2H), 7.5 (d, J = 7.5 Hz, 2H),  8.0 (s, 1H).  HRMS (ESI) calcd for [C36H43N3O5+Na]
+: 













2'-isobutyl-2-oxospiro[indoline-3,3'-pyrrolidine]-4'-carboxylate (A-3): Prepared via 
the general procedure in 78% yield as a white solid. 1H NMR: δ  0.54 (d, J = 6.0 Hz, 3H), 
0.57 (d, J = 6.0 Hz, 3H), 0.87-0.90 (m, 1H), 1.0-1.1 (m, 2H), 1.4-1.5 (m, 1H), 3.1 (s, 3H), 
3.8 (q, J = 10 Hz, 2H), 4.3 (d, J = 11 Hz, 1H), 4.4 (dd, J = 6, 15 Hz, 1H), 4.6 (dd, J = 6, 
15 Hz, 1H), 4.6 (d, J = 5.0 Hz, 1H), 5.4 (d, J = 5.0 Hz, 1H), 6.9 (t, J = 5.0 Hz, 1H), 6.9 
(d, J =  7.5 Hz, 2H), 7.1-7.3 (m, 10H), 7.3 (d, J = 7.5 Hz, 2H), 7.4 (d, J = 7.0 Hz, 2H), 7.5 
(s, 2H)  8.3 (s, 1H).  HRMS (ESI) calcd for [C39H41N3O5+Na]





carboxylate (A-4): Prepared via the general procedure in 65% yield as a white solid. 1H 
NMR: δ  0.25 (d, J = 6.4 Hz, 3H), 0.44 (d, J = 6.4 Hz, 3H), 0.92 (t, J = 10.4 Hz, 2H), 1.2 
 170 
(t, J = 14 Hz, 1H), 3.2 (s, 3H), 3.4 (s, 1H) 3.4-3.5 (m, 2H) 3.6 (m, 1H), 3.7-3.8 (m, 3H), 
3.8-3.9 (m, 2H),  4.6 (d, J = 8.4 Hz, 1H), 5.4 (d, J = 8.4 Hz, 1H), 6.7 (d, J = 7.2 Hz, 1H), 
6.9 (d, J = 7.6 Hz, 1H), 7.0 (t, J = 6.8 Hz, 1H), 7.2-7.5 (m, 6H), 7.5 (t, J = 7.6 Hz, 2H), 
7.7 (d, J = 6.8 Hz, 2H), 7.8  (d, J = 6.8 Hz, 2H) HRMS (ESI) calcd for 
[C33H37N3O6+Na]













carboxylate (A-5):  Prepared via the general procedure in 76% yield as a white solid. 1H 
NMR: δ  0.51 (d, J = 6.5 Hz, 6H), 0.98-1.0 (m, 2H), 1.4-1.5 (m, 1H), 3.0 (s, 3H), 3.7 (d, J 
= 9.5 Hz, 1H), 3.9 (d, J = 9.5 Hz, 1H), 4.2 (dd, J = 2.5, 10 Hz, 1H), 4.6 (d, J = 6.5 Hz, 
1H), 4.8 (dd, J = 5.0, 15 Hz, 1H), 5.0 (dd, J = 6.0, 14 Hz, 1H), 5.4 (d, J = 6.0 Hz, 1H), 
5.9 (t, J = 5.5 Hz, 1H) 6.8 (d, J = 7.5 Hz, 1H), 6.9 (d, J = 7.5 Hz, 1H), 6.9 (t, J = 8.0 Hz, 
1H), 7.1-7.2 (m, 7H), 7.3 (m, 2H), 7.4-7.5 (m, 2H), 7.5 (m, 2H), 7.6 (d, J = 7.0 Hz, 2H), 
7.8 (dd, J = 2.5, 6.5 Hz, 1H), 7.9 (m, 1H), 8.1 (m, 1H),  8.1 (s, 1H).  MS (ESI) calcd for 
[C43H43N3O5+Na]





carboxylate (A-6): Prepared via the general procedure in 59% yield as a white solid. 1H 
NMR: δ  0.56 (d, J = 6.5 Hz, 3H), 0.59 (d, J = 6.5 Hz, 3H), 1.0 (td J = 10, 2.5 Hz, 1H), 
1.1 (m, 1H), 1.5 (td, J = 10, 2.5 Hz, 1H), 3.2 (s, 3H), 3.8 (d, J = 9.0 Hz, 1H), 3.8 (d, J = 
9.0 Hz, 1H), 4.2  (dd, J = 3.5, 11 Hz, 1H), 4.3 (dd, J = 5.5, 15 Hz, 1H), 4.5 (dd, J = 5.5, 
15 Hz, 1H), 4.6 (d, J = 5.5 Hz, 1H), 5.4 (d, J = 5.5 Hz, 1H), 6.1 (t,  J = 6.0 Hz, 1H), 6.9 
(d, J = 7.5 Hz, 1H) 6.9 (d, J = 7.5 Hz, 1H), 7.0 (t, J = 7.5 Hz, 1H), 7.1-7.2 (m, 1H), 7.2-
7.3 (m, 6H), 7.3-7.4 (m, 3H), 7.4 (d, J = 7.0 Hz, 2H), 7.5 (t, J = 7.5 Hz, 2H), 7.6 (dd, J = 







Prepared via the general procedure in 72% yield as a white solid. 1H NMR: δ  0.50 (d, J = 
6.4 Hz, 3H), 0.56 (d, J = 6.4 Hz, 3H), 0.98 (d,  J =  6.8 Hz, 3H), 1.0-1.1 (m, 1H), 1.4 (d, 
J = 6.4 Hz, 3H), 1.2-1.3 (m, 2H), 1.5 (m, 1H),  3.1 (s, 3H), 3.7 (dd, J = 9.4, 13 Hz, 2H), 
4.0 (m, 1H), 4.2 (dd, J = 3.2, 10 Hz, 1H), 4.6  (d, J = 5.2 Hz, 1H), 4.7 (s, 1H) (d, J = 5.2 
Hz, 1H), 5.5 (d, J = 8.0 Hz, 1H), 6.9 (d, J = 7.5 Hz, 1H) 6.8 (t, J = 7.2 Hz, 2H), 6.9 (m, 
1H), 7.1-7.2 (m, 7H), 7.3 (d, J = 7.6 Hz, 2H), 7.5 (d, J = 7.6 Hz, 2H), 8.2 (s, 1H).  
HRMS (ESI) calcd for [C35H41N3O5+Na]













2'-isobutyl-2-oxospiro[indoline-3,3'-pyrrolidine]-4'-carboxylate (A-8): Prepared via 
the general procedure in 79% yield as a white solid. 1H NMR: δ  0.55 (d, J = 6.4 Hz, 3H), 
0.62 (d, J = 6.0 Hz, 3H), 0.85-0.93 (m, 4H), 1.0-1.1 (m, 2H), 1.2-1.5 (m, 4H), 3.2 (s, 3H), 
3.2 (m, 2H), 3.7 (dd, J = 9.4, 19 Hz, 2H), 4.2  (dd, J = 3.5, 9.4 Hz, 1H), 4.3 (d, J = 5.0 Hz, 
1H), 4.8 (s, 1H), 5.4 (d, J = 5.0 Hz, 1H), 6.8 (t, J = 3.5 Hz, 2H), 6.9 (dd, J = 7.6, 15 Hz, 
2H), 7.1-7.3 (m, 6H), 7.4  (d, J = 7.2 Hz, 2H) 7.5 (d, J = 7.2 Hz, 1H) HRMS (ESI) calcd 
for [C36H43N3O5+Na]




pyrrolidine]-4'-carboxylate (A-9): Prepared via the general procedure in 16% yield as a 
pale yellow oil. 1H NMR: δ  0.75 (d, J = 6.8 Hz, 6H), 0.83-0.88 (m 1H), 1.1 (d, J = 6.8 
Hz, 3H), 1.2 (d, J = 6.4 Hz, 3H), 1.6 (sept, J = 6.0 Hz, 1H) 3.2 (s, 3H), 3.5 (d, J = 5.6 Hz, 
1H), 3.9 (d, J = 7.6 Hz, 1H),  4.0 (m, 1H), 4.5 (d, J = 7.6 Hz, 1H), 6.9 (d, J = 7.6 Hz, 1H) 
7.0 (t, J = 7.6 Hz, 1H), 7.1 (s, 1H), 7.1-7.2 (m, 2H), 8.1 (s, 1H).  MS (ESI) calcd for 
[C21H29N3O4+Na]
+: 410.2, found: 410.2. 
 
(2'S,3R,4'R)-methyl 2'-isobutyl-5'-(isobutylcarbamoyl)-2-oxospiro[indoline-3,3'-
pyrrolidine]-4'-carboxylate (A-10): Prepared via the general procedure in 46% yield as 
a pale yellow oil. 1H NMR: δ  0.79 (d, J = 3.6 Hz, 6H), 0.79-0.94 (m, 2H), 0.95 (d, J = 
6.4 Hz, 6H), 1.5 (sept, J = 6.8 Hz, 1H), 1.8 (sept, J = 6.8 Hz, 1H) 2.0-3.1 (m, 2H), 3.2 (s, 
3H), 3.5 (dd, J = 4, 9.2 Hz, 1H), 3.9 (d, J = 7.6 Hz, 1H),  4.6 (d, J = 7.6 Hz, 1H), 6.9 (d, J 
= 7.6 Hz, 1H) 7.0 (t, J = 7.6 Hz, 1H), 7.1 (d, J = 7.6 Hz, 1H), 7.2 (d, J = 7.6 Hz, 1H), 7.4 
(s 1H), 8.3 (s, 1H).  MS (ESI) calcd for [C22H31N3O4+Na]





Prepared via the general procedure in 55% yield as a pale yellow solid. 1H NMR: δ  3.3 (s, 
3H), 5.1 (s, 1H), 5.2 (d, J = 10 Hz, 1H),  6.3 (d, J = 4.0 Hz, 1H), 6.6 (d, J = 10 Hz, 1H) 
6.9 (t, J = 10 Hz, 1H), 7.0-7.3 (m, 16H), 7.6 (s, 1H).  MS (ESI) calcd for 
[C34H28N2O5+Na]
+: 567.2 found: 567.2. 
 
(2'S,3R,4'R)-methyl 5'-(butylcarbamoyl)-1'-((1S,2R)-2-hydroxy-1,2-diphenylethyl)-
2-oxo-2'-phenylspiro[indoline-3,3'-pyrrolidine]-4'-carboxylate (A-11): Prepared via 
the general procedure in 79% yield as an ivory solid. 1H NMR: δ 0.89 (t, J =  7.6 Hz, 3H), 
1.2-1.4 (m, 4H), 3.2 (s, 3H), 3.2 (quart, J = 6.8 Hz, 2H). 3.9 (d, J = 8.8 Hz, 1H), 4.0 (d, J 
= 8.4 Hz, 1H) 4.6 (d, J = 4.8 Hz, 1H),  5.1 (d, J = 4.4 Hz, 1H), 5.2 (s, 1H), 5.6 (t, J = 
2.5Hz, 1H),  6.6 (d, J = 7.2 Hz, 1H), 7.0-7.3 (m, 18H), 7.5 (s, 1H), 7.5 (s, 1H).  MS (ESI) 
calcd for [C38H39N3O5+Na]





carboxylate (A-14): Prepared via the general procedure in 53% yield as a white solid. 1H 
NMR: δ 3.2 (s, 3H), 3.7 (s, 3H). 4.1 (d, J = 8.0 Hz, 1H), 4.2 (d, J = 3.2 Hz, 1H) 4.9 (s, 
1H),  5.1 (d, J = 8.0 Hz, 1H), 6.2 (d, J = 3.2 Hz, 1H), 6.5-6.6 (m, 3H), 7.0-7.3 (m, 15H), 
7.6 (s, 1H).  MS (ESI) calcd for [C35H30N2O6+Na]




Prepared via the general procedure in 76% yield as a white solid. 1H NMR: δ 0.94 (t, J = 
7.5 Hz, 3H), 1.2-1.5 (m, 4H) 3.2 (s, 3H), 3.2 (dd, J = 7.0, 13 Hz, 2H), 3.7 (s, 3H),  3.9 (dd, 
J = 8.5, 14 Hz, 2H), 4.6 (d, J = 4.5 Hz, 1H) 5.1 (d, J = 4.0 Hz, 1H), 5.2 (s, 1H) 5.6 (t, J = 
6.0 Hz, 1H), 6.6-6.7 (m, 3H), 6.9-7.0 (m, 4H), 7.0-7.2 (m, 10H), 7.5 (s, 1H), 7.6 (d, J = 
7.0 Hz, 1H).  MS (ESI) calcd for [C39H34N3O6+Na]
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